<SEC-DOCUMENT>0001193125-20-191602.txt : 20200713
<SEC-HEADER>0001193125-20-191602.hdr.sgml : 20200713
<ACCEPTANCE-DATETIME>20200713091033
ACCESSION NUMBER:		0001193125-20-191602
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20200712
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200713
DATE AS OF CHANGE:		20200713

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MEDNAX, INC.
		CENTRAL INDEX KEY:			0000893949
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-HOSPITALS [8060]
		IRS NUMBER:				263667538
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12111
		FILM NUMBER:		201024416

	BUSINESS ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323
		BUSINESS PHONE:		9543840175

	MAIL ADDRESS:	
		STREET 1:		1301 CONCORD TERRACE
		CITY:			SUNRISE
		STATE:			FL
		ZIP:			33323

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PEDIATRIX MEDICAL GROUP INC
		DATE OF NAME CHANGE:	19950801
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d82405d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:md="http://www.mednax.com/20200712" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>Form 8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-07-12_to_2020-07-12">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-07-12_to_2020-07-12">0000893949</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="md-20200712.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-07-12_to_2020-07-12"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000893949</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-07-12</xbrli:startDate> <xbrli:endDate>2020-07-12</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="font-size:10pt;width:8.5in;margin:0 auto"> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <p style="margin-bottom:0px;margin-top:4pt"></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">UNITED STATES</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0pt;margin-top:0pt">SECURITIES AND EXCHANGE COMMISSION</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Washington, D.C. 20549</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:9pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0px;margin-top:9pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-07-12_to_2020-07-12">8-K</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:9pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:9pt">CURRENT REPORT</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Pursuant to Section 13 or 15(d)</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">of the Securities Exchange Act of 1934</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:9pt">Date of Report (date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-07-12_to_2020-07-12" format="ixt:datemonthdayyearen">July 12, 2020</ix:nonNumeric></p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:9pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:24pt;margin-bottom:0px;margin-top:9pt"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2020-07-12_to_2020-07-12">MEDNAX, INC.</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">(Exact Name of Registrant as Specified in Its Charter)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:9pt;margin-bottom:0px">&#160;</p></div>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:9pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-07-12_to_2020-07-12" format="ixt-sec:stateprovnameen">Florida</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-07-12_to_2020-07-12">001-12111</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-07-12_to_2020-07-12">26-3667538</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(State or Other Jurisdiction<br />of Incorporation)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Commission</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">File Number)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(IRS Employer<br />Identification No.)</p></td></tr></table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:9pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:99%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-07-12_to_2020-07-12">1301 Concord Terrace</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-07-12_to_2020-07-12">Sunrise</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2020-07-12_to_2020-07-12" format="ixt-sec:stateprovnameen">Florida</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-07-12_to_2020-07-12">33323</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Address of principal executive office) (zip code)</p></td></tr></table> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:9pt">Registrant&#8217;s telephone number, including area code <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2020-07-12_to_2020-07-12">(954)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-07-12_to_2020-07-12">384-0175</ix:nonNumeric></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:9pt">N/A</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Former name or former address, if changed since last report.)</p> <div style="text-align:center"> <p style="line-height:6pt;margin-left:auto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:9pt;margin-bottom:0px">&#160;</p></div> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:9pt">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-07-12_to_2020-07-12" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-07-12_to_2020-07-12" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12) </span></td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-07-12_to_2020-07-12" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"> <span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr></table> <p style="margin-bottom:0px;margin-top:6pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:4%;vertical-align:top;white-space:nowrap;"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-07-12_to_2020-07-12" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#32;</td>
<td style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"> <span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr></table> <p style="font-family:Times New Roman;text-align:justify;font-size:10pt;margin-bottom:0px;margin-top:12pt">Securities registered pursuant to Section 12(b) of the Act:</p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Title of each class</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Trading</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Symbol(s)</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Name of each exchange</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">on which registered</p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-07-12_to_2020-07-12">Common Stock, par value $.01 per share</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-07-12_to_2020-07-12">MD</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2020-07-12_to_2020-07-12" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></p></td></tr></table> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="font-family:Times New Roman;margin-left:0%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:12pt">Emerging growth company <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-07-12_to_2020-07-12" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Times New Roman;font-weight:normal">&#9744;</span></p> <p style="margin-bottom:0px;margin-top:10pt"></p> <div style="text-align:center"> <p style="line-height:0.5pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:0pt">&#160;</p></div> <div style="text-align:center"> <p style="line-height:3pt;border-bottom:0.50px solid #000000;width:100%;margin-top:0pt;margin-bottom:2pt">&#160;</p></div> <p style="font-family:Times New Roman;text-align:justify;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;1.01 </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Entry into a Material definitive Agreement.</td> </tr> </table> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">Agreement with Starboard Value LP </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt">On&#160;July 12, 2020, MEDNAX, Inc., a Florida corporation (the &#8220;<span style="font-weight:Bold;font-style:normal">Company</span>&#8221;), entered into an agreement (the &#8220;<span style="font-weight:Bold;font-style:normal">Agreement</span>&#8221;) with Starboard Value LP and certain of its affiliates (collectively, &#8220;<span style="font-weight:Bold;font-style:normal">Starboard</span>&#8221;), regarding, among other things, the membership and composition of the Company&#8217;s Board of Directors (the &#8220;<span style="font-weight:Bold;font-style:normal">Board</span>&#8221;) and committees thereof. As of July&#160;12, 2020, Starboard beneficially owns, in the aggregate, 8,450,000 shares, or approximately 9.9% of the Company&#8217;s common stock, issued and outstanding. </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">Pursuant to the Agreement, the Company (i)&#160;accepted the resignations of each of Cesar L. Alvarez, Michael B. Fernandez, Pascal J. Goldschmidt, M.D., Carlos Migoya and Enrique J. Sosa, Ph.D. (collectively, the &#8220;<span style="font-weight:Bold;font-style:normal">Departing Directors</span>&#8221;) as members of the Board and from any Board committee memberships, (ii)&#160;concurrently with the resignations by the Departing Directors, appointed each of Thomas A. McEachin, Mark S. Ordan, Guy P. Sansone, John M. Starcher, Jr. and Shirley A. Weis (each an &#8220;<span style="font-weight:Bold;font-style:normal">Independent Appointee</span>&#8221; and collectively, the &#8220;<span style="font-weight:Bold;font-style:normal">Independent Appointees</span>&#8221;) as directors of the Company with terms expiring at the Company&#8217;s 2020 Annual Meeting of Shareholders (the &#8220;<span style="font-weight:Bold;font-style:normal">2020 Annual Meeting</span>&#8221;); (iii)&#160;subject to their consent to serve, agreed to nominate the Independent Appointees (including any replacement directors pursuant to the Agreement) and Karolyn D. Barker, Waldemar A. Carlo, M.D., Paul G. Gabos, Manuel Kadre, Roger J. Medel M.D. and Michael Rucker (collectively, the &#8220;<span style="font-weight:Bold;font-style:normal">Continuing Directors</span>&#8221;) for election to the Board at the 2020 Annual Meeting for terms expiring at the Company&#8217;s 2021 Annual Meeting of Shareholders (the &#8220;<span style="font-weight:Bold;font-style:normal">2021 Annual Meeting</span>&#8221;); (iv) agreed to recommend, support and solicit proxies for the election of the Independent Appointees at the 2020 Annual Meeting in the same manner as it recommends, supports, and solicits proxies for the election of the Continuing Directors; (v)&#160;agreed to determine that each of the Independent Appointees is deemed to be (a)&#160;a member of the &#8220;Incumbent Board&#8221; or an &#8220;Applicable Director&#8221; (as such term may be defined in the definition of &#8220;Change in Control,&#8221; &#8220;Change of Control&#8221; (or any similar term) under certain of the Company&#8217;s compensation plans, equity plans, and similar internal documents and (b)&#160;a member of the Board as of the beginning of any applicable measurement period for the purposes of the definition of &#8220;Change in Control&#8221; or any similar term under the Company&#8217;s compensation plans, equity plans, and similar internal documents; (vi)&#160;accepted the resignation of Cesar L. Alvarez as Chair of the Board and appointed Mr.&#160;Sansone as Chair of the Board for the duration of the Standstill Period (as defined below); (vii) accepted the irrevocable resignation of Dr.&#160;Medel as a <span style="white-space:nowrap">non-employee</span> director and from all applicable committees of the Board effective upon the conclusion of the 2021 Annual Meeting (the &#8220;<span style="font-weight:Bold;font-style:normal">Retirement Date</span>&#8221;); (viii) agreed that, during the Standstill Period, the Board will not increase the size of the Board to more than 11 directors without Starboard&#8217;s consent; (ix)&#160;agreed to allow Gavin T. Molinelli, a representative of Starboard, as a Board observer during the Standstill Period; (x)&#160;formed a Strategy Committee of the Board (the &#8220;<span style="font-weight:Bold;font-style:normal">Strategy Committee</span>&#8221;) to review, evaluate and oversee the Company&#8217;s corporate strategy and identify opportunities to create value for the Company&#8217;s shareholders; (xi)&#160;appointed the members of the Strategy Committee, the Audit Committee of the Board (the &#8220;<span style="font-weight:Bold;font-style:normal">Audit Committee</span>&#8221;), the Compensation Committee of the Board (the &#8220;<span style="font-weight:Bold;font-style:normal">Compensation Committee</span>&#8221;), the Nominating and Corporate Governance Committee of the Board (the &#8220;<span style="font-weight:Bold;font-style:normal">Nominating and Corporate Governance Committee</span>&#8221;)&#32;and the Medical Science and Technology Committee of the Board (the &#8220;<span style="font-weight:Bold;font-style:normal">Medical Science and Technology Committee</span>&#8221;) as described in Item 5.02 of this Current Report on Form <span style="white-space:nowrap">8-K;</span> and (xii)&#160;disbanded the Executive Committee of the Board (the &#8220;<span style="font-weight:Bold;font-style:normal">Executive Committee</span>&#8221;). </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">With respect to the 2020 Annual Meeting, Starboard has agreed to, among other things, (i)&#160;withdraw its letter to the Company on November&#160;27, 2019 nominating a slate of director candidates to be elected to the Board at the 2020 Annual Meeting and (ii)&#160;vote, subject to certain conditions, all shares of the Company&#8217;s common stock beneficially owned by Starboard in favor of the Company&#8217;s director nominees and in accordance with the Board&#8217;s recommendations on all other proposals, subject to certain limited exceptions. </p> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Starboard also agreed to certain customary standstill provisions, effective as of the date of the Agreement through the earlier of (x)&#160;fifteen (15) business days prior to the deadline for the submission of shareholder nominations for the 2021 Annual Meeting pursuant to the Company&#8217;s Amended and Restated Articles of Incorporation, as amended, <span style="text-decoration:underline">provided</span>, that if the 2021 Annual Meeting has been changed to be more than thirty (30)&#160;calendar days before the date contemplated by the Company&#8217;s 2020 proxy statement or if the date of the 2021 Annual Meeting is scheduled to be more than thirty (30)&#160;calendar days before the <span style="white-space:nowrap">one-year</span> anniversary of the date of the 2020 Annual Meeting, then the Company will provide Starboard with prior written notice of the date of the 2021 Annual Meeting at least fifteen (15)&#160;business days before the date on which notice of the date of the 2021 Annual Meeting is given to shareholders or made public, whichever first occurs, or (y) 100 days prior to the first anniversary of the 2020 Annual Meeting (the &#8220;<span style="font-weight:Bold;font-style:normal">Standstill Period</span>&#8221;), prohibiting Starboard from, among other things: (i)&#160;soliciting proxies or consents with respect to securities of the Company; (ii)&#160;entering into a voting agreement or forming, joining or participating in a &#8220;group&#8221; with other stockholders of the Company, other than certain affiliates of Starboard; (iii)&#160;seeking or submitting or encouraging any person to submit nominees in furtherance of a contested solicitation for the appointment, election or removal of directors; (iv)&#160;submitting any proposal for consideration by stockholders of the Company at any annual or special meeting of stockholders or through any written consent, soliciting a third party to make an acquisition proposal, commenting on any third-party acquisition proposal or calling or seeking a special meeting of stockholders or act by written consent; (v)&#160;seeking, alone or in concert with others, representation on the Board other than as described above; or (vi)&#160;advising, encouraging, supporting, or influencing any person with respect to the voting or disposition of the Company&#8217;s common stock. </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">During the Standstill Period, and for so long as Starboard beneficially owns at least 3.0% of the Company&#8217;s then-outstanding common stock or 2,566,025 shares of the Company&#8217;s common stock (subject to adjustment for stock splits, reclassifications, combinations and similar adjustments), whichever is lesser (the &#8220;<span style="font-weight:Bold;font-style:normal">Minimum Ownership Threshold</span>&#8221;), if any Independent Appointee (or any&#32;replacement director) ceases to be a director for any reason, Starboard may recommend a replacement independent director who meets the criteria specified in the Agreement. </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Company and Starboard also made certain customary representations, agreed to mutual <span style="white-space:nowrap">non-disparagement</span> provisions and agreed to jointly issue a press release announcing certain terms of the Agreement. The Company also agreed to reimburse Starboard for its reasonable, documented <span style="white-space:nowrap">out-of-pocket</span> fees and expenses (including legal fees) incurred in connection with Starboard&#8217;s involvement with the Company though the date of the Agreement, not to exceed $1.2&#160;million in the aggregate. </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which is filed with this Current Report on Form <span style="white-space:nowrap">8-K</span> as Exhibit 10.1 and is incorporated herein by reference. </p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;"> <span style="font-weight:Bold;font-style:normal">Item&#160;5.02 </span> </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;"> <span style="font-weight:Bold;font-style:normal">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span> </td> </tr> </table> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">Appointment of Mark S. Ordan as Chief Executive Officer</p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt">On July 12, 2020, Mr. Ordan was appointed as Chief Executive Officer of the Company, and Mr. Ordan and a wholly-owned subsidiary of the Company entered into an employment agreement (the &#8220;<span style="font-weight:Bold;font-style:normal">Ordan Employment Agreement</span>&#8221;). Pursuant to the Ordan Employment Agreement, Mr. Ordan is to receive, among other things and subject to certain exceptions and conditions set forth therein, (i) an annual base salary of $1 million (prorated for 2020); (ii) a one-time payment in 2020 equal to $250,000 for developing a strategic plan for the Company&#8217;s transformation; (iii) a target annual incentive bonus equal to 150% of his annual base salary (prorated and payable at target for 2020) based on performance metrics to be determined annually by the Compensation Committee; (iv) a restricted stock grant under the Company&#8217;s Amended and Restated 2008 Incentive Compensation Plan (the &#8220;<span style="font-weight:Bold;font-style:normal">2008 Plan</span>&#8221;) with a fair value equal to $2 million, which must be held until the earlier of (x) the fifth anniversary of the grant date and (y) the date of the closing of a change in control, subject to certain exceptions set forth in the Ordan Employment Agreement; (v) a performance stock option grant under the 2008 Plan with a fair value equal to $3 million, a three-year term, requiring one year of service and with performance vesting terms set forth in the Ordan Employment Agreement; (vi) an equity grant in 2021 and future years with a fair value equal to $3.5 million based on performance metrics to be determined annually by the Compensation Committee; (vii) benefits and perquisites consistent with those provided to other senior executive officers of the Company; (viii) customary non-competition, non-solicitation, non-disparagement and confidentiality provisions; (ix) severance for a termination without &#8220;cause&#8221; or for &#8220;good reason&#8221; equal to two times Mr. Ordan&#8217;s base salary, plus two times the greater of&#32;Mr. Ordan&#8217;s target annual performance bonus or his average annual performance bonus for the three prior years, plus a pro rata bonus for the year of termination based on actual performance and the acceleration of certain equity awards and certain other benefits; and (x) severance upon termination in connection with a change in control equal to three times Mr. Ordan&#8217;s base salary, plus three times the greater of Mr. Ordan&#8217;s target annual performance bonus or his average annual performance bonus for the three prior years, plus a pro rata bonus for the year of termination based on actual performance and the acceleration of certain equity awards and certain other benefits.</p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">The foregoing description of the Ordan Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the Ordan Employment Agreement, a copy of which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020.</p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">There are no family relationships among Mr. Ordan any of the Company&#8217;s directors or executive officers. Other than as described in this Current Report on Form 8-K, since the beginning of the Company&#8217;s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which the Company was or is to be a participant and in which Mr. Ordan had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:18pt"> <span style="font-weight:Bold;font-style:normal">Board and Committee Changes</span> </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt">The disclosures set forth in Item 1.01 of this Current Report on Form 8-K with respect to the Board composition are incorporated by reference into this Item 5.02.</p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">On July 12, 2020, (i) the Departing Directors&#8217; resignations from the Board and any committee memberships thereof, (ii) the Independent Appointees&#8217; concurrent appointments to the Board, (iii) the appointment of Mr. Sansone as Chair of the Board and (iv) the naming of Mr. Molinelli as a Board observer, became effective. Additionally, as contemplated by the Agreement, (i) the Strategy Committee will be composed of Messrs. Kadre, McEachin, Sansone and Starcher, with Mr. Sansone as Chair; (ii) the Audit Committee will be composed of Ms. Barker and Messrs. Gabos, McEachin and Rucker, with Mr. Gabos as Chair; (iii) the Compensation Committee will be composed of Dr. Carlo, Messrs. Kadre and Starcher and Ms. Weis, with Ms. Weis serving as Chair; (iv) the Nominating and Corporate Governance Committee will be composed of Ms. Barker, Messrs. Kadre, McEachin and Starcher and Ms. Weis, with Mr. Kadre as Chair, (v) the Medical Science and Technology Committee will be composed of Drs. Carlo and Medel and Messrs. Rucker and Starcher, with Dr. Carlo as Chair; and (vi) the Board disbanded the Executive Committee.</p> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0pt;margin-top:0pt">No directors of the Company resigned because of a disagreement with the Company on any matter relating to the Company&#8217;s operations, policies, or practices.</p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">Upon his or her appointment, each Independent Appointee (other than Mr. Ordan) will receive the standard compensation received by the Company&#8217;s non-employee directors for service on the Board and committees thereof, described in the section entitled &#8220;Director Compensation&#8221; in the Company&#8217;s Annual Report on Form 10-K/A filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on April 28, 2020. In addition, each such director (and Mr. Ordan) will enter into an Indemnification Agreement with the Company, on substantially the terms contained in the Company&#8217;s standard form previously filed with the SEC, which provides for indemnification of the indemnitee to the fullest extent allowed by Florida law.</p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">Other than as described in this Current Report on Form 8-K, since the beginning of the Company&#8217;s last fiscal year, the Company has not engaged in any transactions, and there are no proposed transactions, or series of similar transactions, in which the Company was or is to be a participant and in which any Independent Appointee had a direct or indirect material interest in which the amount involved exceeds or exceeded $120,000.</p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">The biographical information for the Independent Appointees is as follows:</p> <p style="font-family:Times New Roman;margin-left:4%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:12pt"> <span style="font-weight:Bold;font-style:normal">Thomas A. McEachin</span>, age 67,<span style="font-weight:Bold;font-style:normal">&#32;</span>has served on the Board of Directors of RTI Surgical Holdings, Inc. (NASDAQ: RTIX), a global implant company which designs, manufactures and distributes orthopedic and other surgical implants for use in various surgical procedures, since December 2015. Previously, he held executive positions at Covidien Surgical Solutions, a division of Covidien plc (formerly NYSE: COV), a global health care products company and manufacturer of medical devices and supplies, from 2008 to 2012. During his tenure at Covidien Surgical Solutions, he served as Vice President, Finance from 2008 to 2011 and Vice President and Group Chief Financial Officer from 2011 to 2012. From 1997 to 2008, Mr. McEachin served in various finance capacities at United Technologies Corporation (NYSE: UTX), a global leader in the aerospace and building industries, and its subsidiaries, including as chief Investor Relations officer, Vice President and Controller of Pratt &#038; Whitney, and Vice President and Chief Financial Officer of UTC Power. Prior to that, he held several executive positions with Digital Equipment Corporation (formerly NYSE: DEC), a vendor of computer systems, including computers, software, and peripherals, from 1986 to 1997. Mr. McEachin was with Xerox Corporation (n/k/a Xerox Holdings Corporation) (NYSE: XRX), a global corporation that sells print and digital document products and services, from 1975 to 1986, serving as Controller of the procurement organization. Mr. McEachin formerly served as a trustee and officer of the Wadsworth Atheneum (Hartford, CT), the oldest public art institution in the United States, serving on their executive, finance and investment committees. He also is a past board member of the Connecticut Science Center and chair of the audit committee. Mr. McEachin holds a B.S. from New York University and an MBA from Stanford University.</p> <p style="font-family:Times New Roman;margin-left:4%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:12pt"> <span style="font-weight:Bold;font-style:normal">Mark S. Ordan</span>, age 61,<span style="font-weight:Bold;font-style:normal">&#32;</span>most recently served as the Chief Executive Officer and Chairman of the board of directors of Quality Care Properties, Inc. (NYSE:QCP) (&#8220;QCP&#8221;), a self-managed and self-administered real estate investment trust (&#8220;REIT&#8221;) and one of the nation&#8217;s largest actively-managed real estate companies focused on post-acute/skilled nursing and memory care/assisted living properties, from October 2016 to July 2018. Prior to joining QCP, he served as a consultant to HCP, Inc. (NYSE:HCP), a REIT which invests primarily in real estate serving the United States healthcare industry, from March 2016 until QCP&#8217;s spin-off from HCP, Inc. in October 2016. Mr. Ordan previously held several positions at Washington Prime Group Inc. (NYSE:WPG), a retail REIT, including as a director from May 2014 to May 2017, Non-Executive Chairman of the board of directors from January 2016 to June 2016, Executive Chairman from January 2015 to January 2016, and Chief Executive Officer from May 2014 until January 2015. From January 2013 to November 2013, Mr. Ordan served as a director and as the Chief Executive Officer of Sunrise Senior Living, LLC, the successor to the management business of Sunrise Senior Living, Inc. (formerly NYSE:SZR) (&#8220;Sunrise&#8221;), which had been an operator of approximately 300 senior living communities in the United States, Canada and the United Kingdom, prior to its sale in January 2013. Mr. Ordan served as Sunrise&#8217;s Chief Executive Officer from November 2008 to January 2013, as its Chief Investment and Administrative Officer from March 2008 to November 2008 and as a director from July 2008 to January 2013. While at Sunrise, Mr. Ordan led its restructuring and oversaw its eventual sale to Health Care REIT, Inc. Prior to Sunrise, he served as the Chief Executive Officer and President of The Mills Corporation (&#8220;Mills&#8221;) (formerly NYSE:MLS), an owner and manager of a diversified portfolio of regional shopping malls and retail entertainment centers, from October 2006 to May 2007, as its Chief Operating Officer from February 2006 to October 2006 and as </p> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;margin-left:4%;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">a director from December 2006 until March 2007. While at Mills, Mr. Ordan oversaw its operations and its eventual sale to Simon Property Group, Inc. and Farallon Capital Management, L.L.C. in April 2007. Prior to Mills, he served as the President and Chief Executive Officer of Balducci&#8217;s LLC, a gourmet food store chain. He also founded and served as Chairman, President and Chief Executive Officer of Fresh Fields Markets, Inc., an organic foods supermarket chain, eventually leading the merger of the company with Whole Foods Markets, Inc. Mr. Ordan was also previously employed in the equities division of the investment banking firm of Goldman Sachs &#038; Co. Mr. Ordan currently serves as a director at VEREIT, Inc. (NYSE:VER) (f/k/a American Realty Capital Properties, Inc.), a leading, full-service real estate operating company with investment management capability, a position he has held since June 2015. Since February 2019, Mr. Ordan has served on the Board of Trustees of Federal Realty Investment Trust (NYSE:FRT), a REIT specializing in the ownership, management, development, and redevelopment of high quality retail assets, where he also previously served from 1996 to 2006, including as Chairman from 2001 to 2006. Mr. Ordan has served on the board of directors of Elli Finance (UK) plc, the parent holding company of Four Seasons Health Care, a private home care operator, since October 2018. Previously, Mr. Ordan served on the board of Forest City Realty Trust, Inc. (formerly NYSE: FCEA), a real estate company that owns, develops, manages and acquires commercial and residential real estate, from April 2018 until its acquisition by a real estate fund of Brookfield Asset Management Inc. (NYSE: BAM) in December 2018. Mr. Ordan currently serves on the boards of the U.S. Chamber of Commerce and the Chesapeake Bay Foundation. Mr. Ordan received a BA from Vassar College and an MBA from Harvard Business School.</p> <p style="font-family:Times New Roman;margin-left:4%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:12pt"> <span style="font-weight:Bold;font-style:normal">Guy P. Sansone</span>, age 55,<span style="font-weight:Bold;font-style:normal">&#32;</span>has served as the Co-Founder, Chairman and Chief Executive Officer of H2 Health, a leading regional provider of physical rehabilitation services and clinician staffing solutions, since February 2020. Prior to that, he served as Managing Director at Alvarez &#038; Marsal in New York, a financial advisory and consulting firm notable for its work in turnaround management and performance improvement of a number of large, high-profile businesses across the globe, where he served as Chairman of the firm&#8217;s Healthcare Industry Group, which he founded in 2004. Mr. Sansone has also served on the Boards of Directors of Magellan Health, Inc. (NASDAQ: MGLN), a healthcare company focused on special populations, complete pharmacy benefits and other specialty areas of healthcare, since March 2019, and Carisk Partners, a risk transfer, care coordination company, since April 2019, and as Non-Executive Chairman of Brookdale Senior Living, Inc. (NYSE: BKD), an owner and operator of senior living and retirement communities, since January 2020. Mr. Sansone has served on the Board of Advisors for Pager, Inc., a mobile healthcare technology company, since March 2017.Previously, Mr. Sansone served on the Boards of Directors of Civitas Solutions, Inc. (formerly NYSE:CIVI), a leading national provider of home-and community-based health and human services to must-serve individuals with intellectual, developmental, physical or behavioral disabilities and other special needs, from December 2009 until its acquisition by Celtic Intermediate Corp. in March 2019, and HealthPRO Heritage, a leading national provider of therapy management and consulting services, from September 2015 to November 2019. Over the past 20 years, he has invested in and consulted as an executive to numerous companies, focusing on developing and evaluating strategic and operating alternatives designed to enhance value. Mr. Sansone earned a B.S. from the State University of New York at Albany.</p> <p style="font-family:Times New Roman;margin-left:4%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:12pt"> <span style="font-weight:Bold;font-style:normal">John M. Starcher, Jr</span>., age 49,<span style="font-weight:Bold;font-style:normal">&#32;</span>is the President and Chief Executive Officer of Bon Secours Mercy Health, a not-for-profit Catholic health system that owns and operates 48 acute care hospitals, over 1,000 sites of care serving more than 10 million patients and has more than 60,000 employees across seven states and two countries, where he has served since September 2018. Prior to this, he served as Chief Executive Officer and President of Mercy Health from April 2016 to August 2018, where he oversaw the development of system strategies and operations for all 23 Mercy Health hospitals and the clinically integrated network across Ohio and Kentucky. Before being promoted to Chief Executive Officer at Mercy Health, Mr. Starcher served as an Executive Vice President of Operations and Chief Executive Officer of the Cincinnati Market at Mercy Health from January 2015 to April 2016. From August 2013 through March 2014, Mr. Starcher served as the Interim President and Chief Executive Officer of Health Management Associates Inc. (formerly NYSE:HMA) (&#8220;HMA&#8221;), an integrated acute care delivery system with 71 hospitals across 15 states, where he guided HMA through its successful sale to Community Health Systems. Prior to that, Mr. Starcher served as President of HMA&#8217;s Eastern Group from February 2012 until August 2013. Before joining HMA, Mr. Starcher served as the Chief Executive Officer of three of Mercy Health&#8217;s four divisions &#8211; overseeing more than 20 acute care hospitals, five long term care facilities, six home health agencies and dozens of affiliated clinical practices with more than $3 billion in net revenue. Prior to that, he served as the Chief Executive Officer of the Northeastern Pennsylvania Region, the senior vice president of Human Resources and corporate associate general counsel at Catholic Health Partners. Mr. Starcher started his career in 1993 in Human Resources at </p> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;margin-left:4%;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">the Medical College of Ohio as the Director of Labor Relations where he worked until he joined Catholic Health Partners in 1999. Mr. Starcher serves as a Director on the Boards of Bon Secours Mercy Health, The Innovation Institute the Catholic Medical Mission Board and American Pain Consortium, LLC. He also serves on the Advisory Board of HealthQuest Capital. Mr. Starcher holds a Bachelor&#8217;s degree in business administration from Bowling Green State University and a Doctorate in Jurisprudence from the University of Toledo. He is licensed to practice law in the State of Ohio (currently inactive) and has actively served as a director on more than 20 boards in varied industries, including banking, insurance, acute and sub-acute healthcare, specialty care and physician practice organizations.</p> <p style="font-family:Times New Roman;margin-left:4%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:12pt"> <span style="font-weight:Bold;font-style:normal">Shirley A. Weis</span>, age 67,<span style="font-weight:Bold;font-style:normal">&#32;</span>has served as the President of Weis Associates, LLC, a consulting firm she founded focused on healthcare management, strategic planning and leadership development, since January 2014.<span style="font-weight:Bold;font-style:normal">&#32;</span>She has also served as a Senior Advisor to Leavitt Partners, LLC, a health care consulting firm, since February 2014 and as a Special Advisor to the President and Professor of Practice in the W. P. Carey School of Business and the College of Nursing and Health Innovation at Arizona State University, from August 2014 until June 2018. Previously, Ms. Weis was the Vice President and Chief Administrative Officer of Mayo Clinic, a nonprofit medical practice and medical research group, from 2007 until her retirement in December 2013. She joined Mayo Clinic in 1995 and held a number of clinical and administrative leadership positions, including Chair of Administrative Services for the Mayo Clinic in Arizona, Chair of the Mayo Clinic Managed Care Department and Executive Director of Mayo Management Services, Inc. Ms. Weis was also previously a member of the Mayo Clinic Board of Trustees and served as the Secretary for the Mayo Clinic Board of Governors. Prior to joining the Mayo Clinic, she was the Chief Operating Officer of Blue Care Network, a Health Maintenance Organization, and the Emergency Department Manager for Lansing General Hospital. Ms. Weis has served on the Boards of Directors of RTI Surgical Holdings, Inc. (NASDAQ:RTIX), a leading global surgical implant company, since October 2014 and The Medical Memory, LLC, a Phoenix-based, private company that facilitates recording of medical conversations with doctors and distributes them to patients and families, since July 2017. She previously served on the Boards of Directors of Sentry Insurance Company, a mutual insurance company specializing in business insurance, from May 2015 until April 2019, and Traverse Global Healthcare, a Phoenix-based developer of U.S. - style healthcare facilities in global markets, from February 2014 until the company was dissolved in October 2016. Ms. Weis also served on the Michigan State University College of Nursing Board of Visitors and is a distinguished author and public speaker. She is Emeritus Assistant Professor in the Mayo Clinic College of Medicine and has also taught healthcare leadership at the University of Minnesota&#8217;s Carlson School of Management, Michigan State University, University of Wisconsin-LaCrosse, Lansing Community College and for the Michigan Hospital Association. Ms. Weis holds a BSN in Nursing from Michigan State University and a Master&#8217;s degree in management from Aquinas College. She also received an honorary Doctor of Science degree from Michigan State University. Ms. Weis has been named a Michigan State University Distinguished Alumna and has received the Diana Award for Outstanding Business Women. She was also named one of the Top 25 Women in Healthcare by Modern Healthcare magazine for 2007 and 2013 and the National Association of Professional Women&#8217;s &#8220;Woman of the Year Award&#8221; for 2012.</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:18pt"> <span style="font-weight:Bold;font-style:normal">Retirement of Dr. Medel as Chief Executive Officer</span> </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt">On July 12, 2020, Dr. Medel, the Chief Executive Officer of the Company and a member of the Board, retired from his capacity as Chief Executive Officer, effective immediately. Dr. Medel will continue to serve as a non-employee member of the Board until the 2021 Annual Meeting. In addition, Dr. Medel will serve as a consultant to the Company pursuant to a Consulting Agreement entered into with a wholly-owned subsidiary of the Company, for up to a twelve-month term (the &#8220;<span style="font-weight:Bold;font-style:normal">Consulting Agreement</span>&#8221;), for which he will receive a monthly fee of $177,083.33. In the event that the wholly-owned subsidiary of the Company terminates the Consulting Agreement prior to the end of such twelve-month term, other than for material breach by Dr. Medel, Dr. Medel will receive a lump sum payment equal to the unpaid fees for each month remaining in the term.</p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">In connection with Dr. Medel&#8217;s retirement, Dr. Medel entered into a Separation Agreement with a wholly-owned subsidiary of the Company (the &#8220;<span style="font-weight:Bold;font-style:normal">Separation Agreement</span>&#8221;). Dr. Medel&#8217;s retirement is a termination without &#8220;Cause&#8221; (as defined in that certain Employment Agreement, dated as of August 7, 2011, as amended, between a wholly-owned subsidiary of the Company and Dr. Medel, the &#8220;<span style="font-weight:Bold;font-style:normal">Medel Employment Agreement</span>&#8221;) and pursuant to the Separation Agreement, Dr. Medel will receive the applicable severance benefits provided under the Medel Employment Agreement. In addition, upon the earlier of (i) completion of the twelve-month term of the Consulting Agreement or (ii) termination of the Consulting Agreement by the wholly-owned subsidiary of the Company for any reason other than material breach by Dr. Medel, any outstanding unvested restricted shares granted to Dr. Medel prior to his retirement will fully vest as of such date. Dr. Medel has entered into a customary release of the Company and reaffirmed and agreed to comply with the restrictive covenants set forth in the Medel Employment Agreement.</p> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0pt;margin-top:0pt">The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the Separation Agreement (including the Consulting Agreement), which is filed as Exhibit 10.2 to this Current Report on Form&#160;8-K and is incorporated herein by reference.</p> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:18pt"> <span style="font-weight:Bold;font-style:normal">Amendments to Employment Agreements</span> </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt">On July 12, 2020, each of Stephen D. Farber, the Company&#8217;s Executive Vice President and Chief Financial Officer, and Dominic J. Andreano, the Company&#8217;s Executive Vice President, General Counsel and Secretary, entered into a second amendment (the &#8220;<span style="font-weight:Bold;font-style:normal">Second Amendments</span>&#8221;) to their respective Amended and Restated Employment Agreements with a wholly-owned subsidiary of the Company, each dated as of February 13, 2020, as amended (the &#8220;<span style="font-weight:Bold;font-style:normal">Employment Agreements</span>&#8221;), pursuant to which, among other things, (i) each executive agreed that he will not terminate his employment for &#8220;Good Reason&#8221; (as defined in the Employment Agreements) during the 60-day period after the date of the Settlement Agreement, which such executive is entitled to do under his Employment Agreement as a result of Dr. Medel no longer being the senior most executive officer of the Company; (ii) the wholly-owned subsidiary of the Company may not terminate the executive&#8217;s employment for &#8220;Cause&#8221; (as defined in the Employment Agreements) during the 91-day period beginning on the date of the Settlement Agreement, and (iii) all &#8220;Equity Awards&#8221; (as defined in the Employment Agreements) granted to the executive by the Company prior to the date of the Settlement Agreement will become fully vested as of the date of the Settlement Agreement, in connection with which each executive entered into a customary release of the Company.</p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">The foregoing description of the Second Amendments does not purport to be complete and is qualified in its entirety by reference to the Second Amendments, which are filed as Exhibits 10.3 and 10.4 to this Current Report on Form&#160;8-K and are incorporated herein by reference.</p> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;7.01&#32;</td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Regulation FD Disclosure.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt">On July&#160;13, 2020, the Company issued a press release announcing the Company&#8217;s entry into the Agreement with Starboard, the retirement of Dr.&#160;Medel, the appointment of Mr.&#160;Ordan, the resignations of the Departing Directors and the appointments of the Independent Appointees. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 under the Exchange Act, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as may be expressly set forth by specific reference to such filing. </p> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:18pt">Important Additional Information and Where You Can Find It </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt">The Company, its directors and certain of its executive officers may be deemed to be participants in a solicitation of proxies from the Company&#8217;s shareholders at its 2020 Annual Meeting in connection with the matters to be considered at the 2020 Annual Meeting. Information regarding the Company&#8217;s directors and executive officers and their respective interests in the Company, by security holdings or otherwise, will be set forth in the Company&#8217;s Definitive Proxy Statement for its 2020 Annual Meeting, to be filed with the SEC, and reports filed by the Company and ownership forms filed by its directors and executive officers with the SEC. The Company will furnish its Definitive Proxy Statement for its 2020 Annual Meeting to shareholders entitled to vote at the meeting and will file a copy with the SEC. The Company urges its shareholders to carefully read the Definitive Proxy Statement for its 2020 Annual Meeting, and any other relevant documents filed by the Company with the SEC, when available because they will contain important information. Shareholders will be able to receive the proxy statement and other relevant documents free of charge at the SEC&#8217;s website at www.sec.gov or at www.mednax.com. </p> <p style="margin-bottom:0px;margin-top:18pt"></p>
<table cellspacing="0" cellpadding="0" border="0" style="font-family:Times New Roman;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:10%;vertical-align:top;white-space:nowrap;">Item&#160;9.01 </td>
<td style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Financial Statements and Exhibits.</td> </tr> </table> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:6pt">(d)<span style="font-style:Italic">&#160;Exhibits</span></p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;text-decoration:underline;font-size:10pt;margin-bottom:0px;margin-top:24pt">Exhibit Index </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td></td>
<td></td>
<td></td>
<td style="width:5%;"></td>
<td style="width:92%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td colspan="2" style="white-space:nowrap;vertical-align:bottom;text-align:center;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Exhibit </p> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt;border-bottom:1pt solid #000000;display:inline-block">Number </p> </td>
<td style="white-space:nowrap;vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;display:inline-block;">&#160;</td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt;border-bottom:1pt solid #000000;display:inline-block">Description of Exhibit </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">10.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d82405dex101.htm">Agreement, dated as of July&#160;12, 2020, by and among MEDNAX, Inc., Starboard Value LP and certain of its affiliates. </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">10.2 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d82405dex102.htm">Separation Agreement, dated July&#160;12, 2020, by and between MEDNAX Services, Inc. and Roger J. Medel, M.D. </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">10.3</p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d82405dex103.htm">Second Amendment to Amended and Restated Employment Agreement, dated as of July&#160;12, 2020, by and between MEDNAX Services, Inc. and Stephen D. Farber. </a> </p> </td> </tr> </table> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-left:auto;margin-right:auto">
<tr>
<td></td>
<td></td>
<td></td>
<td style="width:5%;"></td>
<td style="width:92%;"></td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">10.4</p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d82405dex104.htm">Second Amendment to Amended and Restated Employment Agreement, dated as of July&#160;12, 2020, by and between MEDNAX Services, Inc. and Dominic J. Andreano. </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">99.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d82405dex991.htm">Press Release of MEDNAX, Inc. dated July&#160;13, 2020. </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Times New Roman;font-size:10pt;margin-bottom:0pt;margin-top:0pt">104 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Cover Page Interactive Data File (embedded within the Inline XBRL document). </p> </td> </tr> </table> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />
 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Times New Roman;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">SIGNATURES </p> <p style="font-family:Times New Roman;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:0px;margin-right:auto">
<tr>
<td style="width:46%;"></td>
<td style="width:1%;"></td>
<td style="width:4%;"></td>
<td></td>
<td style="width:2%;"></td>
<td style="width:1%;"></td>
<td style="width:45%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">MEDNAX, INC. </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td>
<td style="height:16px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Date: July&#160;13, 2020 </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">By: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;margin-bottom:1pt;font-size:10pt;margin-top:0pt;border-bottom:1px solid #000000">/s/ Stephen D. Farber </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt"></p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Stephen D. Farber </p> <p style="font-family:Times New Roman;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Chief Financial Officer </p> </td> </tr> </table> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>
 </body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d82405dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement
(this &#147;<U>Agreement</U>&#148;) is made and entered into as of July&nbsp;12, 2020 by and among MEDNAX, Inc. (the &#147;<U>Company</U>&#148;) and the entities and natural persons set forth in the signature pages hereto (collectively,
&#147;<U>Starboard</U>&#148;) (each of the Company and Starboard, a &#147;<U>Party</U>&#148; to this Agreement, and collectively, the &#147;<U>Parties</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the
Company and Starboard have engaged in various discussions and communications concerning the Company&#146;s business, financial performance and strategic plans; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date hereof, Starboard has a beneficial ownership (as determined under Rule <FONT STYLE="white-space:nowrap">13d-3</FONT>
promulgated under the Securities Exchange Act of 1934, as amended, or the rules or regulations promulgated thereunder (the &#147;<U>Exchange Act</U>&#148;)) interest in the Common Stock, $0.01 par value per share, of the Company (the <U>Common
Stock</U>&#148;) totaling, in the aggregate, 8,450,000 shares, or approximately 9.9% of the Common Stock issued and outstanding on the date hereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Starboard submitted a letter to the Company on November&nbsp;27, 2019 (the &#147;<U>Nomination Notice</U>&#148;) nominating a slate
of director candidates to be elected to the Board of Directors of the Company (the &#147;<U>Board</U>&#148;) at the Company&#146;s 2020 Annual Meeting of Shareholders (the &#147;<U>2020 Annual Meeting</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, as of the date hereof, the Company and Starboard have determined to come to an agreement with respect to the composition of the Board
and certain other matters, as provided in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants and agreements contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto, intending to be legally bound hereby, agree as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Board Appointments; Leadership Structure and Related Agreements</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Board Appointments</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees that effective upon the execution of this Agreement, the Board and all applicable committees of
the Board shall take or shall have taken all necessary actions to (A)&nbsp;accept the resignations tendered by Cesar L. Alvarez, Michael B. Fernandez, Pascal J. Goldschmidt, M.D., Carlos A. Migoya and Enrique J. Sosa, Ph.D. as directors of the
Company, who the Company hereby represents have submitted, or shall no later than the date hereof submit, letters of resignation to the Board that will become effective upon the execution of this Agreement and (B)&nbsp;appoint Thomas A. McEachin,
Mark Ordan, Guy P. Sansone, John M. Starcher, Jr. and Shirley A. Weis (each a &#147;<U>Starboard Independent Appointee</U>&#148; and collectively, the &#147;<U>Starboard Independent Appointees</U>&#148;) as directors of the Company with terms
expiring at the 2020 Annual Meeting. The Company agrees that, subject to their consent to serve, the Board shall nominate (A)&nbsp;the Starboard Independent Appointees and (B)&nbsp;Roger J. Medel M.D., Paul G. Gabos, Manuel
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Kadre, Karolyn D. Barker, Michael Rucker and Waldemar A. Carlo, M.D. (the &#147;<U>Continuing Directors</U>&#148;) for election to the Board at the 2020 Annual Meeting for terms expiring at the
Company&#146;s 2021 Annual Meeting of Shareholders (the &#147;<U>2021 Annual Meeting</U>&#148;) and shall recommend, support and solicit proxies for the election of the Starboard Independent Appointees at the 2020 Annual Meeting in the same manner
as it recommends, supports and solicits proxies for the election of the Continuing Directors. The Company shall use its reasonable efforts to hold the 2020 Annual Meeting no later than September&nbsp;10, 2020. The Company shall use its reasonable
best efforts to hold the 2021 Annual Meeting no later than May&nbsp;28, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If any Starboard Independent
Appointee (or any Starboard Replacement Director (as defined below)) is unable or unwilling to serve as a director and ceases to be a director, resigns as a director, is removed as a director, or for any other reason fails to serve or is not serving
as a director at any time prior to the expiration of the Standstill Period (as defined below), and at such time Starboard beneficially owns (as determined under Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated under the Exchange Act)
in the aggregate at least the lesser of 3% of the Company&#146;s then-outstanding Common Stock and 2,566,025 shares of Common Stock (subject to adjustment for stock splits, reclassifications, combinations and similar adjustments)(the
&#147;<U>Minimum Ownership Threshold</U>&#148;), Starboard shall have the ability to recommend a person to be a Starboard Replacement Director in accordance with this <U>Section</U><U></U><U>&nbsp;1(a)(ii)</U> (any such replacement nominee, when
appointed to the Board, shall be referred to as a &#147;<U>Starboard Replacement Director</U>&#148;). Any Starboard Replacement Director must (A)&nbsp;be reasonably acceptable to the Board (such acceptance not to be unreasonably withheld), (B)
qualify as &#147;independent&#148; pursuant to New York Stock Exchange (&#147;<U>NYSE</U>&#148;) listing standards, (C)&nbsp;have the relevant financial and business experience to be a director of the Company, and (D)&nbsp;unless otherwise consented
to by the Board and the Nominating and Corporate Governance Committee, be independent, and not be an Affiliate (as defined below), of Starboard (for the avoidance of doubt, the nomination by Starboard of such person to serve on the board of any
other company shall not, in and of itself, cause such person to not be deemed independent of Starboard). The Nominating and Corporate Governance Committee of the Board (the &#147;<U>Nominating and Corporate Governance Committee</U>&#148;) shall make
its determination and recommendation regarding whether such Starboard Replacement Director meets the foregoing criteria within five (5)&nbsp;business days after (1)&nbsp;such nominee has submitted to the Company the documentation required by
<U>Section</U><U></U><U>&nbsp;1(c)(iv)</U>, including such nominee&#146;s consent to a customary background check, and (2)&nbsp;representatives of the Board have conducted customary interview(s) of such nominee, if such interviews are requested by
the Board or the Nominating and Corporate Governance Committee. The Company shall use its reasonable best efforts to conduct the background check and any interview(s) contemplated by this <U>Section</U><U></U><U>&nbsp;1(a)(ii)</U> as promptly as
practicable, but in any case, with respect to the interview(s), assuming reasonable availability of the nominee, within ten (10)&nbsp;business days after Starboard&#146;s submission of such nominee. In the event the Nominating and Corporate
Governance Committee does not accept a person recommended by Starboard as the Starboard Replacement Director, Starboard shall have the right to recommend additional substitute person(s) whose appointment shall be subject to the Nominating and
Corporate Governance Committee recommending such person in accordance with the procedures described above. Upon the recommendation of a Starboard Replacement Director nominee by the Nominating and Corporate Governance Committee, the Board shall vote
on the appointment of such Starboard Replacement Director to the Board no later than five (5)&nbsp;business days after the Nominating and Corporate Governance Committee&#146;s recommendation of such Starboard Replacement Director; <U>provided</U>,
<U>however</U>, that if the Board does not appoint such Starboard Replacement Director to the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Board pursuant to this <U>Section</U><U></U><U>&nbsp;1(a)(ii)</U>, the Parties shall continue to follow the procedures of this <U>Section</U><U></U><U>&nbsp;1(a)(ii)</U> until a Starboard
Replacement Director is elected to the Board. Subject to NYSE rules and applicable law, upon a Starboard Replacement Director&#146;s appointment to the Board, the Board and all applicable committees of the Board shall take all necessary actions to
appoint such Starboard Replacement Director to any applicable committee of the Board of which the replaced director was a member immediately prior to such director&#146;s resignation or removal. Subject to NYSE rules and applicable law, until such
time as any Starboard Replacement Director is appointed to any applicable committee of the Board, one of the other Starboard Independent Appointees (as designated by Starboard) will serve as an interim member of such applicable committee. Any
Starboard Replacement Director designated pursuant to this <U>Section</U><U></U><U>&nbsp;1(a)(ii)</U> replacing a Starboard Independent Appointee prior to the mailing of the Company&#146;s definitive proxy statement for the 2020 Annual Meeting shall
stand for election at the 2020 Annual Meeting together with the other director nominees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Concurrent with the
execution of this Agreement, Dr.&nbsp;Medel shall execute and deliver to the Company an advance irrevocable resignation letter pursuant to which he shall resign from the Board and all applicable committees thereof effective upon conclusion of the
2021 Annual Meeting (the &#147;<U>Retirement Date</U>&#148;). At the Retirement Date, the Board and all applicable committees of the Board shall take all necessary actions to accept the resignation of Dr.&nbsp;Medel from the Board and all applicable
committees thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;The Company hereby confirms that, concurrently with the execution of this Agreement, the
Company and Dr.&nbsp;Medel have entered into a Separation Agreement (the &#147;<U>Separation Agreement</U>&#148;) pursuant to which, among other things, Dr.&nbsp;Medel has retired as Chief Executive Officer of the Company. Prior to the date of this
Agreement, a true copy of the fully executed Separation Agreement has been furnished to Starboard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp; The
Company agrees that immediately following the execution of this Agreement, the Board and all applicable committees of the Board shall take all necessary actions to appoint Mr.&nbsp;Sansone as Chair of the Board. Mr.&nbsp;Sansone shall continue to
serve in such position for the duration of the Standstill Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;During the period commencing with the date
of this Agreement through the expiration of the Standstill Period, the Board and all applicable committees of the Board shall not increase the size of the Board to more than eleven (11)&nbsp;directors <U>provided</U>, <U>however</U>, the Board may
be increased during this period upon Starboard&#146;s prior written consent to increase the size of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees that the Board, which includes the Starboard Independent Appointees, will hold a meeting of
the Board no later than prior to the opening of trading on the NYSE on the first business day following the date of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees that during the Standstill Period, Gavin T. Molinelli shall be an observer to the Board (the
&#147;<U>Starboard Observer</U>&#148;) and shall receive copies of all documents distributed to the Board during the Standstill Period, including notice of all meetings of the Board, all written consents executed by the Board, all materials prepared
for consideration at any meeting of the Board, and all minutes related to each meeting of the Board contemporaneous </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with their distribution to the Board. The Starboard Observer shall have the right to attend and participate, but not vote, at all meetings of the Board during the Standstill Period (whether such
meetings are held in person, telephonically or otherwise). For the avoidance of doubt, the Starboard Observer shall have the right to request and shall be granted access to all of the documents that are accessible by all members of the Board. In
addition, the Starboard Observer shall have the right to attend and participate, but not vote, at all meetings of the Strategy Committee (as defined below), the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;) and
the Nominating and Corporate Governance Committee during the Standstill Period (whether such meetings are held in person, telephonically or otherwise) and shall receive copies of all documents distributed to such committees during the Standstill
Period, including notice of all meetings of such committees, all written consents executed by such committees, all materials prepared for consideration at any meeting of such committees, and all minutes related to each meeting of such committees
contemporaneous with their distribution to the members of such committees. The Starboard Observer will agree to comply with all confidentiality, corporate governance, conflict of interest, Regulation FD, code of conduct and ethics, and insider
trading policies and guidelines of the Company that have been provided to the Starboard Observer. Notwithstanding the foregoing, the Company reserves the right to exclude the Starboard Observer from access to any material or meeting or portion
thereof if, and only to the extent that, the Board determines reasonably and in good faith that (i)&nbsp;such exclusion is necessary to preserve the attorney-client privilege or (ii)&nbsp;access to such material or meeting or portion thereof could
result in a conflict of interest between Starboard or the Starboard Observer and the Company. As a condition to serving as the Starboard Observer, the Starboard Observer shall deliver to the Company an executed confidentiality agreement in a form to
be agreed between the Parties prior to the date of this Agreement, and shall also agree to hold any information received as the Starboard Observer subject to the fiduciary duties that he or she would have to the Company and its shareholders were he
or she a director of the Company. The Company agrees to indemnify the Starboard Observer to the same extent, and subject to the same conditions and limitations, that all directors of the Company are indemnified by the Company, <U>provided</U> that
the foregoing indemnification shall not be applicable if a court of competent jurisdiction determines that the Starboard Observer either violated the terms of this Agreement, including by breaching his or her fiduciary duties, such as the duty of
loyalty, or the acts in question were the result of the Starboard Observer&#146;s bad faith misconduct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Board Committees</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Strategy Committee</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Immediately following the execution of this Agreement, the Board and all applicable committees of the Board shall take all necessary actions
to (A)&nbsp;form a Strategy Committee of the Board (the &#147;<U>Strategy Committee</U>&#148;) to review, evaluate and oversee the Company&#146;s corporate strategy and identify opportunities to create value for the Company&#146;s shareholders, and
(B)&nbsp;appoint Mr.&nbsp;Kadre, Mr.&nbsp;McEachin, Mr.&nbsp;Sansone, and Mr.&nbsp;Starcher to the Strategy Committee, and appoint Mr.&nbsp;Sansone as its Chair. During the Standstill Period, the Strategy Committee shall be composed of four
(4)&nbsp;directors, including Mr.&nbsp;Kadre, Mr.&nbsp;McEachin, Mr.&nbsp;Sansone, and Mr.&nbsp;Starcher, with Mr.&nbsp;Sansone serving as its Chair. The Strategy Committee will be provided with the resources and authority necessary for the Strategy
Committee to discharge its purpose, including to hire and direct the work of any consultant and/or adviser to assist the Strategy Committee if requested by the Strategy Committee. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Audit Committee.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Immediately following the execution of this Agreement, the Board and all applicable committees of the Board shall take all necessary actions
to appoint Mr.&nbsp;McEachin to the Audit Committee of the Board (the &#147;<U>Audit Committee</U>&#148;). During the Standstill Period, unless otherwise agreed by the Audit Committee, the Audit Committee shall be composed of four
(4)&nbsp;directors, consisting of Ms.&nbsp;Barker, Mr.&nbsp;Gabos, Mr.&nbsp;McEachin, and Mr.&nbsp;Rucker, with Mr.&nbsp;Gabos serving as its Chair. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Compensation Committee.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Immediately following the execution of this Agreement, the Board and all applicable committees of the Board shall take all necessary actions
to (A)&nbsp;appoint Mr.&nbsp;Starcher and Ms.&nbsp;Weis to the Compensation Committee and (B)&nbsp;appoint Ms.&nbsp;Weis as the Chair of the Compensation Committee. During the Standstill Period, unless otherwise agreed by the Compensation Committee,
the Compensation Committee shall be composed of four (4)&nbsp;directors, consisting of Dr.&nbsp;Carlo, Mr.&nbsp;Kadre, Mr.&nbsp;Starcher, and Ms.&nbsp;Weis, with Ms.&nbsp;Weis serving as its Chair. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;<U>Nominating and Corporate Governance Committee</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Immediately following the execution of this Agreement, the Board and all applicable committees of the Board shall take all necessary actions
to appoint Mr.&nbsp;McEachin, Mr.&nbsp;Starcher and Ms.&nbsp;Weis to the Nominating and Corporate Governance Committee. During the Standstill Period, unless otherwise agreed by the Nominating and Corporate Governance Committee, the Nominating and
Corporate Governance Committee shall be composed of five (5)&nbsp;directors, consisting of Ms.&nbsp;Barker, Mr.&nbsp;Kadre, Mr.&nbsp;McEachin, Mr.&nbsp;Starcher, and Ms.&nbsp;Weis, with Mr.&nbsp;Kadre serving as its Chair. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;<U>Medical Science and Technology Committee</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Immediately following the execution of this Agreement, the Board and all applicable committees of the Board shall take all necessary actions
to appoint Mr.&nbsp;Starcher to the Medical Science and Technology Committee of the Board (the &#147;<U>Medical Science and Technology Committee</U>&#148;). During the Standstill Period, unless otherwise agreed by the Medical Science and Technology
Committee, the Medical Science and Technology Committee shall be composed of four (4)&nbsp;directors, consisting of Dr.&nbsp;Carlo, Dr.&nbsp;Medel, Mr.&nbsp;Rucker, and Mr.&nbsp;Starcher, with Dr.&nbsp;Carlo serving as its Chair. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;<U>Executive Committee</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Immediately following the execution of this Agreement, the Board and all applicable committees of the Board shall take all necessary actions
to cause the Executive Committee of the Board to be disbanded. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;<U>Director Committee Appointments</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Subject to NYSE rules and applicable laws, the Board and all applicable committees of the Board shall take all actions necessary to ensure
that during the Standstill Period, each committee and subcommittee of the Board, including any new committee(s) and subcommittee(s) that may be established, shall include at least one (1)&nbsp;Starboard Independent Appointee (or a Starboard
Replacement Director). Without limiting the foregoing, the Board shall give each of the Starboard Independent Appointees the same due consideration for membership to any committee of the Board as any other independent director. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Agreements</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;Starboard shall comply, and shall cause each of its controlled Affiliates and Associates to comply with the terms
of this Agreement and shall be responsible for any breach of this Agreement by any such controlled Affiliate or Associate. As used in this Agreement, the terms &#147;<U>Affiliate</U>&#148; and &#147;<U>Associate</U>&#148; shall have the respective
meanings set forth in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> promulgated by the Securities and Exchange Commission under the Exchange Act and shall include all persons or entities that at any time during the term of this Agreement become
Affiliates or Associates of any person or entity referred to in this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Starboard, on behalf of
itself and its controlled Affiliates and Associates, hereby irrevocably withdraws its Nomination Notice and any related materials or notices submitted to the Company in connection therewith. During the Standstill Period, except as otherwise provided
herein, Starboard shall not, and shall cause each of its controlled Affiliates and Associates not to, directly or indirectly, (A)&nbsp;nominate or recommend for nomination any person for election at any annual or special meeting of the
Company&#146;s shareholders, (B)&nbsp;submit any proposal for consideration at, or bring any other business before, any annual or special meeting of the Company&#146;s shareholders, or (C)&nbsp;initiate, encourage or participate in any &#147;<U>vote
no,</U>&#148; &#147;<U>withhold</U>&#148; or similar campaign with respect to any annual or special meeting of the Company&#146;s shareholders. Starboard shall not publicly or privately encourage or support any other shareholder, person or entity to
take any of the actions described in this <U>Section</U><U></U><U>&nbsp;1(c)(ii)</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Starboard shall appear
in person or by proxy at the 2020 Annual Meeting and vote all shares of Common Stock beneficially owned by Starboard at the 2020 Annual Meeting (A)&nbsp;in favor of all directors nominated by the Board for election, (B)&nbsp;in favor of the
ratification of the appointment of PricewaterhouseCoopers LLP as the Company&#146;s independent registered public accounting firm for the 2020 fiscal year, (C)&nbsp;in accordance with the Board&#146;s recommendation with respect to the
Company&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> proposal, and (D)&nbsp;in accordance with the Board&#146;s recommendation with respect to any other Company proposal or shareholder
proposal or nomination presented at the 2020 Annual Meeting; <U>provided</U>, <U>however</U>, that in the event Institutional Shareholder Services Inc. (&#147;<U>ISS</U>&#148;) or Glass Lewis&nbsp;&amp; Co., LLC (&#147;<U>Glass Lewis</U>&#148;)
recommends otherwise with respect to the Company&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay&#148;</FONT></FONT> proposal or any other Company proposal or shareholder proposal presented at the 2020
Annual Meeting (other than proposals relating to the election of directors), Starboard shall be permitted to vote in accordance with the ISS or Glass Lewis recommendation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Starboard acknowledges that, prior to the date of this Agreement,
each Starboard Independent Appointee and prior to any appointment, each Starboard Replacement Director, is required to submit to the Company a fully completed copy of the Company&#146;s standard director&nbsp;&amp; officer questionnaire and other
reasonable and customary director onboarding documentation applicable to directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;The Company
agrees that the Board and all applicable committees of the Board shall take all necessary actions, effective no later than immediately following the execution of this Agreement, to determine, in connection with their initial appointment as a
director and nomination by the Company at the 2020 Annual Meeting, that each of the Starboard Independent Appointees is deemed to be (A)&nbsp;a member of the &#147;Incumbent Board&#148; or an &#147;Applicable Director&#148; (as such term may be
defined in the definition of &#147;Change in Control,&#148; &#147;Change of Control&#148; (or any similar term) under the Company&#146;s incentive plans, options plans, equity plans, deferred compensation plans, employment agreements, severance
plans, retention plans, indemnification agreements, loan agreements, or indentures, including, without limitation, the Company&#146;s Employment Agreements with its executive officers, the MEDNAX, Inc. Amended and Restated 2008 Incentive
Compensation Plan, the Pediatrix Medical Group, Inc. 2004 Incentive Compensation Plan, credit agreements, or any other related plans or agreements that refer to any such plan, policy or agreement&#146;s definition of &#147;Change in Control&#148; or
any similar term) and (B)&nbsp;a member of the Board as of the beginning of any applicable measurement period for the purposes of the definition of &#147;Change in Control&#148; or any similar term under the Company&#146;s incentive plans, options
plans, equity plans, deferred compensation plans, employment agreements, severance plans, retention plans, indemnification agreements, loan agreements, or indentures, including, without limitation, the Company&#146;s Employment Agreements with its
executive officers, the MEDNAX, Inc. Amended and Restated 2008 Incentive Compensation Plan, the Pediatrix Medical Group, Inc. 2004 Incentive Compensation Plan and credit agreements. The Company further agrees that during the Standstill Period, the
Company shall not adopt or enter into any incentive plan, option plan, equity plan, deferred compensation plan, employment agreement, severance plan or agreement, change in control plan or agreement, retention plan, loan agreement, indenture, credit
agreement, indemnification agreement or any other material contract or agreement (each a &#147;<U>Future Company Agreement</U>&#148; and collectively, the &#147;<U>Future Company Agreements</U>&#148;), if such Future Company Agreement includes
language regarding the election, appointment or nomination of an individual pursuant to an actual or threatened election contest or any other actual or threatened solicitation of proxies as not being deemed a member of the &#147;Incumbent
Board&#148; or an &#147;Applicable Director&#148; (or any similar term) as such terms may be defined in the definition of, or provisions governing, a &#147;Change in Control&#148; or &#147;Change of Control&#148; (or any similar term) in such Future
Company Agreement or as not being deemed a member of the Board as of the beginning of any applicable measurement period for the purposes of the definition of, or provisions governing, a &#147;Change in Control&#148; or &#147;Change of Control&#148;
(or any similar term) in such Future Company Agreement. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Standstill Provisions</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Starboard agrees that, from the date of this Agreement until the earlier of (x)&nbsp;the date that is fifteen
(15)&nbsp;business days prior to the deadline for the submission of shareholder nominations for the 2021 Annual Meeting pursuant to the Company&#146;s Amended and Restated Articles of Incorporation, as amended, <U>provided</U>, that if the 2021
Annual Meeting has been changed </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be more than thirty (30)&nbsp;calendar days before the date contemplated by the Company&#146;s 2020 proxy statement or if the date of the 2021 Annual Meeting is scheduled to be more than
thirty (30)&nbsp;calendar days before the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the date of the 2020 Annual Meeting, then the Company shall provide Starboard with prior written notice of the date of the 2021 Annual Meeting
at least fifteen (15)&nbsp;business days before the date on which notice of the date of the 2021 Annual Meeting is given to shareholders or made public, whichever first occurs, or (y)&nbsp;the date that is one hundred (100)&nbsp;days prior to the
first anniversary of the 2020 Annual Meeting (the &#147;<U>Standstill Period</U>&#148;), Starboard shall not, and shall cause each of its controlled Affiliates and Associates not to, in each case directly or indirectly, in any manner: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;engage in any solicitation of proxies or become a &#147;<U>participant</U>&#148; in a
&#147;<U>solicitation</U>&#148; (as such terms are defined in Regulation 14A under the Exchange Act) of proxies (including, without limitation, any solicitation of consents that seeks to call a special meeting of shareholders), in each case, with
respect to securities of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;form, join, or in any way knowingly participate in any
&#147;<U>group</U>&#148; (within the meaning of Section&nbsp;13(d)(3) of the Exchange Act) with respect to the shares of the Common Stock (other than a &#147;<U>group</U>&#148; that includes all or some of the members of Starboard, but does not
include any other entities or persons that are not members of Starboard as of the date hereof); <U>provided</U>, <U>however</U>, that nothing herein shall limit the ability of an Affiliate of Starboard to join the &#147;<U>group</U>&#148; following
the execution of this Agreement, so long as any such Affiliate agrees to be bound by the terms and conditions of this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;deposit any shares of Common Stock in any voting trust or subject any shares of Common Stock to any arrangement
or agreement with respect to the voting of any shares of Common Stock, other than any such voting trust, arrangement or agreement solely among the members of Starboard and otherwise in accordance with this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;seek or submit, or knowingly encourage any person or entity to seek or submit, nomination(s) in furtherance of a
&#147;<U>contested solicitation</U>&#148; for the appointment, election or removal of directors with respect to the Company or seek, or knowingly encourage or take any other action with respect to the appointment, election or removal of any
directors, in each case in opposition to the recommendation of the Board; <U>provided</U>, <U>however</U>, that nothing in this Agreement shall prevent Starboard or its Affiliates or Associates from taking actions in furtherance of identifying
director candidates in connection with the 2021 Annual Meeting so long as such actions do not create a public disclosure obligation for Starboard or the Company and are undertaken on a basis reasonably designed to be confidential and in accordance
in all material respects with Starboard&#146;s normal practices in the circumstances; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;(A) make any proposal
for consideration by shareholders at any annual or special meeting of shareholders of the Company, (B)&nbsp;make any offer or proposal (with or without conditions) with respect to any merger, tender (or exchange) offer, acquisition,
recapitalization, restructuring, disposition or other business combination involving Starboard and the Company or any of its subsidiaries, (C)&nbsp;affirmatively solicit a third party to make an offer or proposal (with or without conditions) with
respect to any merger, tender (or exchange) offer, acquisition, recapitalization, restructuring, disposition or other business combination involving the Company or any of its subsidiaries, or publicly encourage, initiate or support any third party
in making such </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an offer or proposal, (D)&nbsp;publicly comment on any third party proposal regarding any merger, tender (or exchange) offer, acquisition, recapitalization, restructuring, disposition, or other
business combination with respect to the Company or any of its subsidiaries by such third party prior to such proposal becoming public, or (E)&nbsp;call or seek to call a special meeting of shareholders; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;seek, alone or in concert with others, representation on the Board, except as specifically permitted in
<U>Section</U><U></U><U>&nbsp;1</U>; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;advise, knowingly encourage, knowingly support or knowingly influence
any person or entity with respect to the voting or disposition of any securities of the Company at any annual or special meeting of shareholders with respect to the appointment, election or removal of director(s), except in accordance with
<U>Section</U><U></U><U>&nbsp;1</U>; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;make any request or submit any proposal to amend the terms of this
Agreement other than through <FONT STYLE="white-space:nowrap">non-public</FONT> communications with the Company or the Board that would not be reasonably determined to trigger public disclosure obligations for any Party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Except as expressly provided in <U>Section</U><U></U><U>&nbsp;1</U> or <U>Section</U><U></U><U>&nbsp;2(a)</U>,
Starboard shall be entitled to (i)&nbsp;vote any shares of Common Stock that it beneficially owns as Starboard determines in its sole discretion and (ii)&nbsp;disclose, publicly or otherwise, how it intends to vote or act with respect to any
securities of the Company, any shareholder proposal or other matter to be voted on by the shareholders of the Company and the reasons therefor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Nothing in <U>Section</U><U></U><U>&nbsp;2(a)</U> shall be deemed to limit the exercise in good faith by any
Starboard Independent Appointee (or a Starboard Replacement Director) of such person&#146;s fiduciary duties solely in such person&#146;s capacity as a director of the Company. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Representations and Warranties of the Company</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company represents and warrants to Starboard that (a)&nbsp;the Company has the corporate power and authority to execute this Agreement and
to bind it thereto, (b)&nbsp;this Agreement has been duly and validly authorized, executed and delivered by the Company, and assuming due execution by each counterparty hereto, constitutes a valid and binding obligation and agreement of the Company,
and is enforceable against the Company in accordance with its terms, except as enforcement thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights
of creditors and subject to general equity principles, (c)&nbsp;prior to entering into this Agreement, the Board was composed of eleven (11)&nbsp;directors and there are no vacancies on the Board and (d)&nbsp;to the actual knowledge of the executive
officers of the Company, the execution, delivery and performance of this Agreement by the Company does not and will not (i)&nbsp;violate or conflict with any law, rule, regulation, order, judgment or decree applicable to the Company, or
(ii)&nbsp;result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both would constitute such a breach, violation or default) under or pursuant to, or result in the loss of a material benefit
under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document or material agreement to which the Company is a party or by which it is bound. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Representations and Warranties of Starboard</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Starboard represents and warrants to the Company that (a)&nbsp;the authorized signatory of Starboard set forth on the signature page hereto
has the power and authority to execute this Agreement and any other documents or agreements to be entered into in connection with this Agreement and to bind Starboard thereto, (b)&nbsp;this Agreement has been duly authorized, executed and delivered
by Starboard, and assuming due execution by each counterparty hereto, is a valid and binding obligation of Starboard, enforceable against Starboard in accordance with its terms except as enforcement thereof may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent conveyance or similar laws generally affecting the rights of creditors and subject to general equity principles, (c)&nbsp;the execution of this Agreement, the consummation of any of the transactions
contemplated hereby, and the fulfillment of the terms hereof, in each case in accordance with the terms hereof, will not conflict with, or result in a breach or violation of the organizational documents of Starboard as currently in effect,
(d)&nbsp;to the actual knowledge of Starboard, the execution, delivery and performance of this Agreement by Starboard does not and will not (i)&nbsp;violate or conflict with any law, rule, regulation, order, judgment or decree applicable to
Starboard, or (ii)&nbsp;result in any breach or violation of or constitute a default (or an event which with notice or lapse of time or both would constitute such a breach, violation or default) under or pursuant to, or result in the loss of a
material benefit under, or give any right of termination, amendment, acceleration or cancellation of, any organizational document, agreement, contract, commitment, understanding or arrangement to which such member is a party or by which it is bound,
(e)&nbsp;as of the date of this Agreement, Starboard is deemed to beneficially own 8,450,000 shares of Common Stock, (f)&nbsp;as of the date hereof, and except as set forth in clause (e)&nbsp;above, Starboard does not currently have, and does not
currently have any right to acquire, any interest in any securities or assets of the Company or its Affiliates (or any rights, options or other securities convertible into or exercisable or exchangeable (whether or not convertible, exercisable or
exchangeable immediately or only after the passage of time or the occurrence of a specified event) for such securities or assets or any obligations measured by the price or value of any securities of the Company or any of its controlled Affiliates,
including any swaps or other derivative arrangements designed to produce economic benefits and risks that correspond to the ownership of shares of Common Stock or any other securities of the Company, whether or not any of the foregoing would give
rise to beneficial ownership (as determined under Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> promulgated under the Exchange Act), and whether or not to be settled by delivery of shares of Common Stock or any other class or series of the
Company&#146;s stock, payment of cash or by other consideration, and without regard to any short position under any such contract or arrangement). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Press Release</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the opening of trading on the NYSE on the first business day following the date of this Agreement, the Company and Starboard shall
jointly issue a mutually agreeable press release (the &#147;<U>Press Release</U>&#148;) announcing certain terms of this Agreement in the form attached hereto as <U>Exhibit A</U>. Prior to the issuance of the Press Release and subject to the terms
of this Agreement, neither the Company (including the Board and any committee thereof) nor Starboard shall issue any press release or make any public announcement regarding this Agreement or the matters contemplated hereby without the prior written
consent of the other Party. During the Standstill Period, neither the Company nor Starboard shall make any public announcement or statement that is materially inconsistent with or contrary to the terms of this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Specific Performance</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of Starboard, on the one hand, and the Company, on the other hand, acknowledges and agrees that irreparable injury to the other Party
hereto would occur in the event any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached and that such injury would not be adequately compensable by the remedies available at law
(including the payment of money damages). It is accordingly agreed that Starboard, on the one hand, and the Company, on the other hand (the &#147;<U>Moving Party</U>&#148;), shall each be entitled to seek specific enforcement of, and injunctive
relief to prevent any violation of, the terms hereof, and the other Party hereto will not take action, directly or indirectly, in opposition to the Moving Party seeking such relief on the grounds that any other remedy or relief is available at law
or in equity. This <U>Section</U><U></U><U>&nbsp;6</U> is not the exclusive remedy for any violation of this Agreement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Expenses</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall reimburse Starboard for its reasonable, documented
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> fees and expenses (including legal expenses) incurred in connection with Starboard&#146;s involvement at the Company through the date of this Agreement,
including, but not limited to its Schedule 13D filings, its preparation and delivery of the Nomination Letter, and the negotiation and execution of this Agreement, provided that such reimbursement shall not exceed $1,200,000 in the aggregate. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severability</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, void or
unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall in no way be affected, impaired or invalidated. It is hereby stipulated and declared to be the
intention of the Parties that the Parties would have executed the remaining terms, provisions, covenants and restrictions without including any of such which may be hereafter declared invalid, void or unenforceable. In addition, the Parties agree to
use their reasonable best efforts to agree upon and substitute a valid and enforceable term, provision, covenant or restriction for any of such that is held invalid, void or enforceable by a court of competent jurisdiction. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Notices</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any notices, consents, determinations, waivers or other communications required or permitted to be given under the terms of this Agreement
must be in writing and will be deemed to have been delivered: (a)&nbsp;upon receipt, when delivered personally; (b)&nbsp;upon confirmation of receipt, when sent by email (<U>provided</U> such confirmation is not automatically generated); or
(c)&nbsp;upon delivery or refusal of delivery when sent by a nationally recognized overnight delivery service, in each case properly addressed to the Party to receive the same. The addresses for such communications shall be: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">1301 Concord Terrace </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sunrise, Florida 33323</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">General Counsel</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-mail:</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">dominic_andreano@mednax.com</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">DLA Piper LLP (US) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">200 South
Biscayne Boulevard, Suite 2500 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Miami, FL 33131 </P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Joshua M. Samek, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">joshua.samek@dlapiper.com</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to Starboard or any member thereof: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Starboard Value LP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">777 Third
Avenue, 18th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10017 </P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jeffrey C. Smith</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Peter A. Feld</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">jsmith@starboardvalue.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">pfeld@starboardvalue.com</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Olshan Frome Wolosky LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1325
Avenue of the Americas </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10019 </P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Attention:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Steve Wolosky, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Andrew Freedman, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">swolosky@olshanlaw.com</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">afreedman@olshanlaw.com</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Applicable Law</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement shall be governed by and construed and enforced in accordance with the laws of the State of Florida without reference to the
conflict of laws principles thereof that would result in the application of the law of another jurisdiction. Each of the Parties hereto irrevocably agrees that any legal action or proceeding with respect to this Agreement and the rights and
obligations arising hereunder, or for recognition and enforcement of any judgment in respect of this Agreement and the rights and obligations arising hereunder brought by the other Party hereto or its successors or assigns, shall be brought and
determined exclusively in Broward County, Florida and any state appellate court therefrom within the State of Florida (or, if the State of Florida declines to accept jurisdiction over a particular matter, any federal court within the Southern
District of Florida). Each of the Parties hereto hereby irrevocably submits with regard to any such action or proceeding for itself and in respect of its property, generally and unconditionally, to the personal jurisdiction of the aforesaid courts
and agrees that it will not bring any action relating to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
this Agreement in any court other than the aforesaid courts. Each of the Parties hereto hereby irrevocably waives, and agrees not to assert in any action or proceeding with respect to this
Agreement, (a)&nbsp;any claim that it is not personally subject to the jurisdiction of the above-named courts for any reason, (b)&nbsp;any claim that it or its property is exempt or immune from jurisdiction of any such court or from any legal
process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise) and (c)&nbsp;to the fullest extent permitted by applicable legal
requirements, any claim that (i)&nbsp;the suit, action or proceeding in such court is brought in an inconvenient forum, (ii)&nbsp;the venue of such suit, action or proceeding is improper or (iii)&nbsp;this Agreement, or the subject matter hereof,
may not be enforced in or by such courts. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement may be executed in two or more counterparts, each of which shall be considered one and the same agreement and shall become
effective when counterparts have been signed by each of the Parties and delivered to the other Party (including by means of electronic delivery or facsimile). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Mutual <FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to applicable law, each of the Parties covenants and agrees that, during the Standstill Period, or if earlier, until such time as the
other Party or any of its agents, subsidiaries, affiliates, successors, assigns, officers, key employees or directors shall have breached this <U>Section</U><U></U><U>&nbsp;12</U>, neither it nor any of its respective agents, subsidiaries,
affiliates, successors, assigns, officers, key employees or directors shall in any way publicly criticize, disparage, call into disrepute or otherwise defame or slander the other Party or such other Party&#146;s subsidiaries, affiliates, successors,
assigns, officers (including any current officer of a Party or a Party&#146;s subsidiaries who no longer serves in such capacity following the execution of this Agreement), directors (including any current officer or director of a Party or a
Party&#146;s subsidiaries who no longer serves in such capacity in connection with the execution of this Agreement), employees, shareholders, agents, attorneys or representatives, or any of their businesses, products or services, in any manner that
would reasonably be expected to damage the business or reputation of such other Party, their businesses, products or services or their subsidiaries, affiliates, successors, assigns, officers (or former officers), directors (or former directors),
employees, shareholders, agents, attorneys or representatives. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Securities Laws</U>. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Starboard acknowledges that it is aware, and will advise each of its representatives who are informed as to the matters that are the subject
of this Agreement, that the United States securities laws may prohibit any person who directly or indirectly has received from an issuer material, <FONT STYLE="white-space:nowrap">non-public</FONT> information from purchasing or selling securities
of such issuer or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell such securities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Entire Agreement; Amendment and Waiver; Successors and Assigns; Third Party Beneficiaries; Term</U>.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Agreement contains the entire understanding of the Parties with respect to its subject matter. There are no
restrictions, agreements, promises, representations, warranties, covenants or undertakings between the Parties other than those expressly set forth herein. No modifications of this Agreement can be made except in writing signed by an authorized
representative of each the Company and Starboard. No failure on the part of any Party to exercise, and no delay in exercising, any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such
right, power or remedy by such Party preclude any other or further exercise thereof or the exercise of any other right, power or remedy. All remedies hereunder are cumulative and are not exclusive of any other remedies provided by law. The terms and
conditions of this Agreement shall be binding upon, inure to the benefit of, and be enforceable by the Parties hereto and their respective successors, heirs, executors, legal representatives, and permitted assigns. No Party shall assign this
Agreement or any rights or obligations hereunder without, with respect to Starboard, the prior written consent of the Company, and with respect to the Company, the prior written consent of Starboard. This Agreement is solely for the benefit of the
Parties and is not enforceable by any other persons or entities. This Agreement shall terminate at the end of the Standstill Period, except provisions of <U>Sections 6</U> through <U>11</U>, <U>Section</U><U></U><U>&nbsp;13</U>, and
<U>Section</U><U></U><U>&nbsp;14</U>, which shall survive such termination. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[The remainder of this page intentionally left blank]
</B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, this Agreement has been duly executed and delivered by the duly
authorized signatories of the Parties as of the date hereof. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>MEDNAX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Manuel Kadre</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Manuel Kadre</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Lead Independent Director</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD VALUE AND OPPORTUNITY MASTER FUND LTD</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Starboard Value LP,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">its investment manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD VALUE AND OPPORTUNITY S LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Starboard Value LP,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">its manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD VALUE AND OPPORTUNITY C LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Starboard Value R LP,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD VALUE R LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Starboard Value R GP LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD VALUE AND OPPORTUNITY MASTER FUND L LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Starboard Value L LP,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD VALUE L LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Starboard Value R GP LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD VALUE X MASTER FUND LTD</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Starboard Value LP,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">its investment manager</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD VALUE LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Starboard Value GP LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD VALUE GP LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Starboard Principal Co LP,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">its member</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD PRINCIPAL CO LP</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Starboard Principal Co GP LLC,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">its general partner</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD PRINCIPAL CO GP LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STARBOARD VALUE R GP LLC</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jeffrey C. Smith</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Jeffrey C. Smith</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Authorized Signatory</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit A </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Press Release </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[See attached.]
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g82405g0713074008037.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR MORE INFORMATION: &nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles Lynch&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President,
Finance and Strategy&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">954-384-0175</FONT></FONT> ext.
5692&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>charles_lynch@mednax.com </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FOR IMMEDIATE RELEASE </U></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX
Announces Leadership and Board Transitions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I> Mark S. Ordan Appointed Chief Executive Officer, Succeeding Company Founder Roger J.
Medel, M.D. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Guy P. Sansone Appointed Chair of Board of Directors </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Significant Board Refreshment, With Five New Independent Directors Appointed to Succeed Five Departing Directors </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company Reaches Agreement with Starboard Value </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FORT LAUDERDALE, Fla.</B> &#151; July&nbsp;13, 2020 &#151; MEDNAX, Inc. (NYSE: MD), the nation&#146;s leading provider of maternal-fetal, newborn and
pediatric subspecialty care, today announced that the Company&#146;s Board of Directors has appointed Mark S. Ordan as Chief Executive Officer, succeeding Roger J. Medel, M.D., the Company&#146;s founder. Dr.&nbsp;Medel will remain a member of the
Board until the 2021 Annual Meeting of Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Since founding this company in 1979, it has been my great honor and privilege to work
alongside MEDNAX&#146;s clinicians and employees over the past 41 years,&#148; said Dr.&nbsp;Medel. &#147;After four decades, I know that this organization&#146;s commitment to <I>Take Great Care of the Patient</I> is stronger than ever. I am
equally committed to ensuring a successful transition, and I am confident that we will touch even more lives and reach new heights for many years to come.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Ordan previously served as Chief Executive Officer of Quality Care Properties, Inc., a publicly traded real estate company and one of the largest
actively managed companies focused on post-acute, skilled nursing and memory care/assisted living properties, since its <FONT STYLE="white-space:nowrap">spin-off</FONT> from HCP, Inc. in 2016 until 2018. In July 2018, Mr.&nbsp;Ordan completed a sale
of the company to Welltower (NYSE: WELL) and Promedica. Mr.&nbsp;Ordan served as Chief Executive Officer of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Washington Prime Group Inc. (NYSE: WPG), a REIT that owns, develops and manages over 100 malls and shopping centers, from 2014 to 2015. During his tenure, he launched the company as a <FONT
STYLE="white-space:nowrap">spin-off</FONT> of the Simon Property Group (NYSE: SPG). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Ordan served as Chief Executive Officer of Sunrise Senior
Living, Inc., a publicly traded operator and owner of approximately 300 senior living communities in the United States, Canada and the United Kingdom, from 2008 to 2013. He led the turnaround and restructuring of Sunrise and oversaw the sale of the
company in January 2013 to Health Care REIT and KKR. Mr.&nbsp;Ordan served as Chief Executive Officer of The Mills Corporation, a publicly traded developer, owner and manager of a diversified portfolio of regional shopping malls and retail
entertainment centers, from 2006 to 2007. Mr.&nbsp;Ordan oversaw Mills&#146; operations and complete restructuring and led the Company&#146;s sale process to Simon Property Group and Farallon Capital Management, in May 2007. Mr.&nbsp;Ordan serves on
the Board of Directors of VEREIT (NYSE: VER) and Federal Realty Investment Trust (NYSE: FRT). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am honored to join MEDNAX&#146;s outstanding team
of passionate physicians, clinicians and employees,&#148; said Mr.&nbsp;Ordan. &#147;Roger is a renowned physician who has built an amazing company. I look forward to working with Guy, Roger, the other Board members and management team to continue
putting patient needs first and creating value for shareholders.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;On behalf of the entire Company, I want to thank Roger for his extraordinary
vision, leadership and contributions to MEDNAX throughout his decades of services as our CEO,&#148; said Manny Kadre, MEDNAX Lead Independent Director. &#147;Under his guidance and leadership, MEDNAX has grown from a single neonatology group into
the nationally recognized organization it is today. Since founding the Company, Roger has instilled a physician- and patient-centric culture that will endure for decades to come. We look forward to his continuing contributions as a member of our
Board of Directors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors Transitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company today also announced that its Board has appointed five new directors: Thomas A. McEachin, Mr.&nbsp;Ordan, Guy P. Sansone, John M. Starcher, Jr. and
Shirley A. Weis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commensurate with these appointments, current directors Cesar L. Alvarez, Michael B. Fernandez, Pascal J. Goldschmidt, M.D., Carlos A.
Migoya and Enrique J. Sosa, Ph.D. have stepped down from the Board. Mr.&nbsp;Sansone has succeeded Mr.&nbsp;Alvarez as Chair of the Board. These changes are effective immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to welcome Tom, Mark, Guy, John and Shirley to the MEDNAX Board of Directors,&#148; said Mr.&nbsp;Kadre. &#147;Together, these
experienced leaders possess deep collective knowledge of the healthcare services industry and I am confident that their unique expertise will further enhance the Board&#146;s capabilities to oversee the execution of the Company&#146;s strategy and
complete its transformation. I would also like to thank Cesar, Michael, Pascal, Carlos and Enrique for their deep dedication and exemplary service to MEDNAX over the years.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am proud to be joining the Board as Chair during such an exciting time for the Company,&#148; said
Mr.&nbsp;Sansone. &#147;I look forward to working with the Board and management team to help realize the remarkable future potential for this Company. I would like to thank Roger for building such an esteemed company, and I am confident that Mark is
the ideal leader to guide MEDNAX into its next chapter.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;MEDNAX is an outstanding company and I believe there is tremendous opportunity to
build upon the strong legacy and foundation that Roger has created,&#148; said Mr.&nbsp;Ordan. &#147;We will continue the Company&#146;s commitment to provide leading health solutions, deliver exceptional care for our patients, and improve patient
outcomes. Our strong network of experienced clinicians will continue to expand and evolve to meet our patients&#146; needs.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreement with
Starboard Value </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These announcements are pursuant to an agreement that MEDNAX has reached with Starboard Value LP and its affiliates
(&#147;Starboard&#148;), an investment firm which owns approximately 9.9% of MEDNAX&#146;s outstanding common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement,
Starboard has withdrawn its director nominations previously submitted to the Company and agreed to support the Board&#146;s full slate of directors at the Company&#146;s 2020 Annual Meeting of Shareholders. Starboard also agreed to abide by
customary standstill provisions and voting commitments. The complete agreement will be filed by the Company with the U.S. Securities and Exchange Commission (&#147;SEC&#148;) as an exhibit to a Current Report on Form
<FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moelis&nbsp;&amp; Company and Barclays are serving as financial advisors and DLA Piper LLP (US) and Cleary
Gottlieb Steen&nbsp;&amp; Hamilton LLP are serving as legal counsel to MEDNAX. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Guy P. Sansone </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Sansone has served as the <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> Chairman and Chief Executive Officer of H2 Health, a leading regional
provider of physical rehabilitation services and clinician staffing solutions, since February 2020. Prior to that, he served as Managing Director at Alvarez&nbsp;&amp; Marsal in New York, a financial advisory and consulting firm notable for its work
in turnaround management and performance improvement of a number of large, high-profile businesses across the globe, where he served as Chairman of the firm&#146;s Healthcare Industry Group, which he founded in 2004. Mr.&nbsp;Sansone has also served
on the Boards of Directors of Magellan Health, Inc. (NASDAQ: MGLN), a healthcare company focused on special populations, complete pharmacy benefits and other specialty areas of healthcare, since March 2019, and Carisk Partners, a risk transfer, care
coordination company, since April 2019, and as <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chairman of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Brookdale Senior Living, Inc. (NYSE: BKD), an owner and operator of senior living and retirement communities, since January 2020. Mr.&nbsp;Sansone has served on the Board of Advisors for Pager,
Inc., a mobile healthcare technology company, since March 2017. Previously, Mr.&nbsp;Sansone served on the Boards of Directors of Civitas Solutions, Inc. (formerly NYSE:CIVI), a leading national provider of
<FONT STYLE="white-space:nowrap">home-and</FONT> community-based health and human services to must-serve individuals with intellectual, developmental, physical or behavioral disabilities and other special needs, from December 2009 until its
acquisition by Celtic Intermediate Corp. in March 2019, and HealthPRO Heritage, a leading national provider of therapy management and consulting services, from September 2015 to November 2019. Over the past 20 years, he has invested in and consulted
as an executive to numerous companies, focusing on developing and evaluating strategic and operating alternatives designed to enhance value. Mr.&nbsp;Sansone earned a B.S. from the State University of New York at Albany. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Thomas A. McEachin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;McEachin has served on
the Board of Directors of RTI Surgical Holdings, Inc. (NASDAQ: RTIX), a global implant company which designs, manufactures and distributes orthopedic and other surgical implants for use in various surgical procedures, since December 2015.
Previously, he held executive positions at Covidien Surgical Solutions, a division of Covidien plc (formerly NYSE: COV), a global health care products company and manufacturer of medical devices and supplies, from 2008 to 2012. During his tenure at
Covidien Surgical Solutions, he served as Vice President, Finance from 2008 to 2011 and Vice President and Group Chief Financial Officer from 2011 to 2012. From 1997 to 2008, Mr.&nbsp;McEachin served in various finance capacities at United
Technologies Corporation (NYSE: UTX), a global leader in the aerospace and building industries, and its subsidiaries, including as chief Investor Relations officer, Vice President and Controller of Pratt&nbsp;&amp; Whitney, and Vice President and
Chief Financial Officer of UTC Power. Prior to that, he held several executive positions with Digital Equipment Corporation (formerly NYSE: DEC), a vendor of computer systems, including computers, software, and peripherals, from 1986 to 1997.
Mr.&nbsp;McEachin was with Xerox Corporation (n/k/a Xerox Holdings Corporation) (NYSE: XRX), a global corporation that sells print and digital document products and services, from 1975 to 1986, serving as Controller of the procurement organization.
Mr.&nbsp;McEachin formerly served as a trustee and officer of the Wadsworth Atheneum (Hartford, CT), the oldest public art institution in the United States, serving on their executive, finance and investment committees. He also is a past board
member of the Connecticut Science Center and chair of the audit committee. Mr.&nbsp;McEachin holds a B.S. from New York University and an MBA from Stanford University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About John M. Starcher, Jr. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Starcher is the
President and Chief Executive Officer of Bon Secours Mercy Health, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> Catholic health system that owns and operates 48 acute care hospitals, over 1,000
sites of care serving more than 10&nbsp;million patients and has more than 60,000 employees across seven states and two countries, where he has served since September 2018. Prior to this, he served as
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Chief Executive Officer and President of Mercy Health from April 2016 to August 2018, where he oversaw the development of system strategies and operations for all 23 Mercy Health hospitals and
the clinically integrated network across Ohio and Kentucky. Before being promoted to Chief Executive Officer at Mercy Health, Mr.&nbsp;Starcher served as an Executive Vice President of Operations and Chief Executive Officer of the Cincinnati Market
at Mercy Health from January 2015 to April 2016. From August 2013 through March 2014, Mr.&nbsp;Starcher served as the Interim President and Chief Executive Officer of Health Management Associates Inc. (formerly NYSE: HMA) (&#147;HMA&#148;), an
integrated acute care delivery system with 71 hospitals across 15 states, where he guided HMA through its successful sale to Community Health Systems. Prior to that, Mr.&nbsp;Starcher served as President of HMA&#146;s Eastern Group from February
2012 until August 2013. Before joining HMA, Mr.&nbsp;Starcher served as the Chief Executive Officer of three of Mercy Health&#146;s four divisions &#150; overseeing more than 20 acute care hospitals, five long term care facilities, six home health
agencies and dozens of affiliated clinical practices with more than $3&nbsp;billion in net revenue. Prior to that, he served as the Chief Executive Officer of the Northeastern Pennsylvania Region, the senior vice president of Human Resources and
corporate associate general counsel at Catholic Health Partners. Mr.&nbsp;Starcher started his career in 1993 in Human Resources at the Medical College of Ohio as the Director of Labor Relations where he worked until he joined Catholic Health
Partners in 1999. Mr.&nbsp;Starcher serves as a Director on the Boards of Bon Secours Mercy Health, The Innovation Institute, the Catholic Medical Mission Board and American Pain Consortium, LLC. He also serves on the Advisory Board of HealthQuest
Capital. Mr.&nbsp;Starcher holds a Bachelor&#146;s degree in business administration from Bowling Green State University and a Doctorate in Jurisprudence from the University of Toledo. He is licensed to practice law in the State of Ohio (currently
inactive) and has actively served as a director on more than 20 boards in varied industries, including banking, insurance, acute and <FONT STYLE="white-space:nowrap">sub-acute</FONT> healthcare, specialty care and physician practice organizations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Shirley A. Weis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms. Weis has served as the
President of Weis Associates, LLC, a consulting firm she founded focused on healthcare management, strategic planning and leadership development, since January 2014. She has also served as a Senior Advisor to Leavitt Partners, LLC, a health care
consulting firm, since February 2014 and as a Special Advisor to the President and Professor of Practice in the W. P. Carey School of Business and the College of Nursing and Health Innovation at Arizona State University, from August 2014 until June
2018. Previously, Ms. Weis was the Vice President and Chief Administrative Officer of Mayo Clinic, a nonprofit medical practice and medical research group, from 2007 until her retirement in December 2013. She joined Mayo Clinic in 1995 and held a
number of clinical and administrative leadership positions, including Chair of Administrative Services for the Mayo Clinic in Arizona, Chair of the Mayo Clinic Managed Care Department and Executive Director of Mayo Management Services, Inc. Ms. Weis
was also previously a member of the Mayo Clinic Board of Trustees and served as the Secretary for the Mayo Clinic Board of Governors. Prior to joining the Mayo Clinic, she was the Chief Operating Officer of Blue Care Network, a Health Maintenance
Organization, and the Emergency Department Manager for Lansing General Hospital. Ms. Weis </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has served on the Boards of Directors of RTI Surgical Holdings, Inc. (NASDAQ:RTIX), a leading global surgical implant company, since October 2014 and The Medical Memory, LLC, a Phoenix-based,
private company that facilitates recording of medical conversations with doctors and distributes them to patients and families, since July 2017. She previously served on the Boards of Directors of Sentry Insurance Company, a mutual insurance company
specializing in business insurance, from May 2015 until April 2019, and Traverse Global Healthcare, a Phoenix-based developer of U.S. - style healthcare facilities in global markets, from February 2014 until the company was dissolved in October
2016. Ms.&nbsp;Weis also served on the Michigan State University College of Nursing Board of Visitors and is a distinguished author and public speaker. She is Emeritus Assistant Professor in the Mayo Clinic College of Medicine and has also taught
healthcare leadership at the University of Minnesota&#146;s Carlson School of Management, Michigan State University, University of Wisconsin-LaCrosse, Lansing Community College and for the Michigan Hospital Association. Ms.&nbsp;Weis holds a BSN in
Nursing from Michigan State University and a Master&#146;s degree in management from Aquinas College. She also received an honorary Doctor of Science degree from Michigan State University. Ms.&nbsp;Weis has been named a Michigan State University
Distinguished Alumna and has received the Diana Award for Outstanding Business Women. She was also named one of the Top 25 Women in Healthcare by Modern Healthcare magazine for 2007 and 2013 and the National Association of Professional Women&#146;s
&#147;Woman of the Year Award&#148; for 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Additional Information and Where You Can Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. (the &#147;Company&#148;), its directors and certain of its executive officers may be deemed to be participants in a solicitation of proxies from
the Company&#146;s shareholders at its 2020 Annual Meeting of Shareholders in connection with the director nominations disclosed above. Information regarding the Company&#146;s directors and executive officers and their respective interests in the
Company, by security holdings or otherwise, will be set forth in the Company&#146;s Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders, to be filed with the SEC, and reports filed by the Company and ownership forms filed by its
directors and executive officers with the SEC. The Company will furnish its Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders to shareholders entitled to vote at the meeting and will file a copy with the SEC. The Company urges
its shareholders to carefully read the Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders, and any other relevant documents filed by the Company with the SEC, when available because they will contain important information.
Shareholders will be able to receive the proxy statement and other relevant documents free of charge at the SEC&#146;s website at www.sec.gov or at <U>www.mednax.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT MEDNAX </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. is a national health solutions
partner comprised of the nation&#146;s leading providers of physician services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based
tools, continuous quality initiatives, consulting services, clinical research and telemedicine to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enhance patient outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional corporations, MEDNAX provides services
through a network of more than 3,000 physicians in all 50 states and Puerto Rico. Additional information is available at <U>www.mednax.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not
limited to, statements relating to the Company&#146;s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or
anticipate will or may occur in the future. These statements are often characterized by terminology such as &#147;believe,&#148; &#147;hope,&#148; &#147;may,&#148; &#147;anticipate,&#148; &#147;should,&#148; &#147;intend,&#148; &#147;plan,&#148;
&#147;will,&#148; &#147;expect,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;positioned,&#148; &#147;strategy&#148; and similar expressions, and are based on assumptions and assessments made by the Company&#146;s management in light of
their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and
the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and
uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company&#146;s most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and its Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> including the sections entitled &#147;Risk Factors&#148;, as well the Company&#146;s current reports on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> filed with the Securities and Exchange Commission, and include the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak on the Company and its financial condition and results of operations;
the effects of economic conditions on the Company&#146;s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; the Company&#146;s relationships with government-sponsored or funded healthcare programs,
including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company&#146;s ability to comply with the terms of its debt financing arrangements; the impact of the divestiture of the Company&#146;s
anesthesiology medical group; whether the Company will be able to complete the divestiture of its radiology medical group and the terms of any such divestiture; the timing and contribution of future acquisitions; the effects of share repurchases;
and the effects of the Company&#146;s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d82405dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SEPARATION AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Separation Agreement (this &#147;<B><I>Agreement</I></B> &#148;) is hereby made and entered into between <B>MEDNAX SERVICES, INC., f/k/a
PEDIATRIX MEDICAL GROUP, INC.</B>, a Florida corporation (&#147;<B><I>Employer</I></B> &#148;), and <B>ROGER J. MEDEL, M.D. </B>(&#147;<B><I>Employee</I></B> &#148;) to be effective as set forth in Section 10 below. Employer and Employee may be
referred to herein as a &#147;<B><I>Party</I></B> &#148; and, together, the &#147;<B><I>Parties</I></B>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Employee was
employed by Employer pursuant to the Employment Agreement with Employer dated August&nbsp;7, 2011, as amended by that certain First Amendment with Employer dated October&nbsp;4, 2017 and Second Amendment dated July&nbsp;1, 2019 (as amended, the
&#147;<B><I>Employment Agreement</I></B>&#148;) (capitalized terms used but not defined in this Agreement have the meanings ascribed thereto in the Employment Agreement); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Employee holds the positions of Chief Executive Officer of MEDNAX and a member of the MEDNAX Board; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Employee&#146;s employment with Employer is being terminated by Employer without Cause; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties have mutually agreed that the date of the Employee&#146;s termination of Employee&#146;s employment will be July&nbsp;12,
2020 (the &#147;<B><I>Separation Date</I></B>&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Parties wish to enter into this Agreement and the Release attached
hereto as <U>Exhibit A</U> (the &#147;<B><I>Release</I></B>&#148;), and the Consulting Agreement attached hereto as <U>Exhibit B</U> (the &#147;<B><I>Consulting Agreement</I></B>&#148;), to set forth the terms and conditions of the Parties&#146;
obligations following the Separation Date; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Employee&#146;s execution and <FONT STYLE="white-space:nowrap">non-revocation</FONT>
of, and compliance with, a release of claims is a condition to receipt of certain severance payments and benefits under the Employment Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW THEREFORE, in consideration of the mutual covenants and mutual benefits contained herein, Employee and Employer agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Separation Date</U>. Employee&#146;s last day of employment with Employer will be the Separation Date. Employee
will be paid, at his regular rate of pay, for any hours worked as an employee of Employer through the Separation Date, regardless of whether or not he signs this Agreement or the Release. As of the Separation Date, except as set forth herein,
Employee is not to hold himself out as an officer, employee, agent, or authorized representative, or negotiate or enter into any agreements on behalf of, Employer or any of its Affiliates (as defined below) or otherwise attempt to bind Employer or
any of its Affiliates, unless instructed in writing to do so by the Chief Executive Officer of Employer. By his signature below, Employee agrees that immediately upon the Separation Date and without any further action or notice on his part, Employee
will be considered to have resigned from any and all positions as an officer or similar of Employer and any of its subsidiaries or Affiliates, other than Employee&#146;s position as a director of MEDNAX. For purposes hereof, the term
&#147;Affiliate&#148; shall mean any corporation, association, partnership, limited liability company, or other legal entity or organization that directly, or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Employer. As used in this definition, the term &#147;control&#148; means the possession,
directly or indirectly, of the power to direct or cause the direction of the management and policies of any such legal entity, whether through ownership of voting securities, by contract, or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consulting Arrangement</U>. Conditioned upon Employee&#146;s signing this Agreement and signing and not revoking
the Release, and complying with the terms of this Agreement and the Release, Employee shall be given the opportunity to provide consulting services to Employer pursuant to the terms of the Consulting Agreement attached hereto as <U>Exhibit B</U>.
Employee shall be required to sign the Consulting Agreement to perform services and receive the consulting fees set forth therein. Employee agrees to waive any notice entitlements under Article 4 of the Employment Agreement in exchange for the
opportunity to provide consulting services pursuant to the Consulting Agreement. The parties hereby intend that the level of Executive&#146;s bona fide services shall be reduced to 20% or less of the average level of bona fide services provided by
Executive during the thirty-six (36)&nbsp;month period immediately preceding the termination of employment and shall be considered a &#147;separation from service&#148; for purposes of Section&nbsp;409A of the Internal Revenue Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment Arrangements; Severance Benefits</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Conditioned upon Employee&#146;s signing this Agreement and signing and not revoking the Release, and complying
with the terms of this Agreement and the Release, Employee will be provided with the following payments and benefits (collectively referred to as the &#147;<B><I>Severance Benefits</I></B>&#148;): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">i.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Severance payments and benefits due to Employee following a termination of his employment by Employer without
Cause under (A)&nbsp;Section&nbsp;5.4 of the Employment Agreement (including Sections 5.10 and 5.11; it being agreed that the amount to be paid to Employee pursuant to the third sentence of Section&nbsp;5.4 on each of the first and second
anniversaries of the Separation Date is $1,125,000.00, representing Employee&#146;s most recent performance bonus paid prior to the Separation Date), (B) Section&nbsp;5.13 of the Employment Agreement, and (C) 5.16 of the Employment Agreement,
provided that with respect to the provision of administrative services, the Company may provide such services directly or reimburse the Employee as mutually agreed upon by the parties; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">ii.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Vesting of three hundred ninety-five thousand, six hundred fifteen (395,615) restricted shares of MEDNAX common
stock, par value $0.01 per share (the &#147;Unvested Shares&#148;), previously granted to Employee by MEDNAX that remain unvested as of the Separation Date, which shall continue to vest until fully vested and automatically vest in full in the
amounts and on the dates set forth below: </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Original Grant Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Vesting Date</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number of Shares</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">March&nbsp;1, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">March&nbsp;1, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">49,146</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">February&nbsp;12, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February&nbsp;12, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59,472</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February&nbsp;12, 2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">59,472</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="center">February&nbsp;13, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February&nbsp;13, 2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">75,842</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February&nbsp;13, 2022</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75,841 </P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">February&nbsp;13, 2023</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75,842</P></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, upon the earlier of (A)&nbsp;completion of the twelve (12)&nbsp;month consulting
term set forth in the Consulting Agreement or (B)&nbsp;termination of the Consulting Agreement by Employer for any reason other than material breach by Employee, any outstanding Unvested Shares shall fully vest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employee acknowledges and agrees that the Severance Benefits are in addition to any other compensation to which Employee would be entitled absent his
execution of a release pursuant to his Employment Agreement and that absent signing and not revoking a release, Employee will not be eligible for, nor shall Employee have a right to receive, any payments from Employer following the Separation Date
other than accrued but unpaid Base Salary and employee benefits as of the end of the Employment Period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Employee acknowledges and agrees that the
Section&nbsp;3(a)ii acceleration of vesting Severance Benefits are in addition to any other compensation to which Employee would be entitled absent his execution of this Agreement and the Release and that absent signing and not revoking this
Agreement and the Release, Employee will not be eligible for, nor shall Employee have a right to receive, said benefits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Any payment or provision of Severance Benefits under this Agreement and the Employment Agreement shall remain
subject to the terms and conditions set forth in Article 5 and Article 8 of the Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Employee
shall serve as a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of the MEDNAX Board until the 2021 annual meeting of shareholders of MEDNAX, subject to his earlier resignation upon not less than fifteen (15)&nbsp;business days&#146;
prior written notice to the MEDNAX Board. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions set forth in this Agreement
including the effectiveness of the Release, no later than five (5)&nbsp;business days following the effectiveness of the Release, Employer shall place the severance amounts payable to Employee under Section&nbsp;5.4 of the Employment Agreement into
a &#147;rabbi trust,&#148; providing for the timely payment of the severance amounts held in the trust. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Post-Separation Obligations</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Employee further reaffirms and agrees to comply with any and all covenants and agreements regarding <FONT
STYLE="white-space:nowrap">non-competition,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidential information, intellectual property and assignment of inventions, return of company property and
<FONT STYLE="white-space:nowrap">non-disparagement</FONT> to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which Employee&#146;s employment was subject, including without limitation the provisions in Section&nbsp;8 (Restrictive Covenants; Confidential Information; Work Product; Injunctive Relief) of
the Employment Agreement, including all subsections thereof, provided, however, that notwithstanding Section&nbsp;8.4 of the Employment Agreement, Employer has agreed that Employee may retain Employer Property following the termination of the
Employment Agreement (subject to the terms of the Employment Agreement) for use during Employee&#146;s service on the MEDNAX Board and Employee&#146;s services pursuant to the Consulting Agreement, and Employee agrees that Employee will return any
such unreturned Employer Property promptly upon Employer&#146;s request. Employee agrees and acknowledges that for purposes of Section&nbsp;8 in the Employment Agreement the &#147;Restricted Period&#148; shall mean the Employment Period plus
twenty-four (24)&nbsp;months from the Separation Date. For the avoidance of doubt, Employer acknowledges that Employee may, and hereby consents to, Employee employing his administrative assistant, Cindy Bobrick, at any time after the Separation
Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Defend Trade Secrets Act of 2016, Employee acknowledges that he shall not have criminal
or civil liability under any federal or state trade secret law for the disclosure of a trade secret that (i)&nbsp;is made (A)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney and
(B)&nbsp;solely for the purpose of reporting or investigating a suspected violation of law; or (ii)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. In addition, if Employee
files a lawsuit for retaliation by Employer for reporting a suspected violation of law, Employee may disclose the trade secret to his attorney and may use the trade secret information in the court proceeding, if he (x)&nbsp;files any document
containing the trade secret under seal and (y)&nbsp;does not disclose the trade secret, except pursuant to court order. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Nothing in this Agreement or in the Release attached hereto prohibits or prevents Employee from filing a charge
with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before the U.S. Equal Employment Opportunity Commission, the National Labor Relations Board, or a similar agency enforcing federal, state, or local
anti-discrimination laws (except that Employee acknowledges that he may not recover any monetary benefits or personal relief in connection therewith).&nbsp;In addition, nothing in this Agreement or in the Release attached hereto,&nbsp;including but
not limited to the release&nbsp;of&nbsp;claims in the Release nor the confidentiality clauses herein, prohibits Employee from: (i)&nbsp;reporting possible violations of federal law or regulations, including any possible securities laws violations,
to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the U.S. Congress, or any agency Inspector General; (ii)&nbsp;making any other disclosures that are
protected under the whistleblower provisions of federal law or regulations; or (iii)&nbsp;otherwise fully participating in any federal whistleblower programs, including but not limited to any such programs managed by the U.S. Securities and Exchange
Commission and/or the Occupational Safety and Health Administration.&nbsp;Moreover, nothing in this Agreement or the Release attached hereto prohibits or prevents Employee from receiving individual monetary awards or other individual relief by
virtue of participating in such&nbsp;federal&nbsp;whistleblower programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consideration Period</U>. Employee
shall have <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days to sign this Agreement, but he may knowingly and voluntarily waive that <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;day period by signing this Agreement
earlier. The consideration period within which Employee will be required to sign and return the Release shall be as set forth in the Release. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law; Dispute Resolution</U>. This Agreement shall be
governed by and construed in accordance with the laws of the State of Florida without regard to its conflict of laws principles to the extent that such principles would require the application of laws other than the laws of the State of Florida. Any
dispute between the Parties related to this Agreement or any agreement referenced herein shall be determined according to the arbitration and dispute resolution provisions set forth in Section&nbsp;9 of the Employment Agreement, <U>provided</U>,
<U>however</U>, that notwithstanding Section&nbsp;9 of the Employment Agreement, (a)&nbsp;if Employee seeks arbitration to enforce the terms of this Agreement, including the Employment Agreement and the Consulting Agreement, Employer shall bear all
costs associated with such arbitration, including but not limited to all costs of the arbitrator, and shall reimburse Employee on a monthly basis for his reasonable legal and other expenses, including all fees, incurred in connection with any such
arbitration, and (b)&nbsp;in the event that Employer brings suit against Employee seeking injunctive relief, Employer agrees to advance all of Employee&#146;s reasonable legal and other expenses, including all fees, incurred by Employee in
connection with such action, <U>provided</U>, <U>however</U>, that if Employer ultimately prevails in seeking injunctive relief, Employee shall reimburse Employer all such advanced legal fees and other expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Acknowledgement</U>. Employee acknowledges that he has read this Agreement, that he has been advised (by
this Agreement) to consult with an attorney before he signs this Agreement, and that he understands all of its terms and signs it voluntarily and with full knowledge of its significance and the consequences thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. The invalidity of any one or more of the words, phrases, sentences, clauses or Sections
contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Contingent Severance Benefits</U>. Employer&#146;s continuing obligations under this Agreement are contingent
upon Employee&#146;s compliance with all terms and conditions provided for in this Agreement and the Release. In the event that Employee breaches any of his obligations under this Agreement or the Release, Employee agrees that Employer may cease
making any severance payments due under this Agreement, and recover all severance payments already made under this Agreement, in addition to all other available legal remedies. For the avoidance of doubt, a breach by Employee or noncompliance of
terms and conditions by Employee under the Consulting Agreement shall not be deemed noncompliance with the terms and conditions provided for in this Agreement and the Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective Date</U>. Conditioned on all Parties executing it, this Agreement shall be considered effective as of
July&nbsp;12, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Entire Agreement</U>. Prior to the Separation Date, the Employment Agreement shall
remain in full force and effect, except where the Employment Agreement and this Agreement conflict, in which case this Agreement shall control. As of the Separation Date, this Agreement, including the Release and Consulting Agreement attached hereto
and the other documents referenced herein, and the surviving provisions of the Employment Agreement shall constitute the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
entire agreement between the Parties with respect to Employee&#146;s former employment with Employer and the Parties&#146; relationship and obligations to each other; provided that any equity
awards held by Employee shall be governed by the applicable equity plan and grant documents, and the Employment Agreement&#146;s provisions regarding Employee&#146;s vesting rights, including accelerated vesting rights, shall continue in full force
and effect, in each case as modified by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Assignment; Third Party Beneficiaries</U>. This
Agreement and all rights of Employee under this Agreement shall inure to the benefit of and be enforceable by Employee&#146;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If
Employee should die before all Severance Benefits have been received by Employee, then such remaining Severance Benefits shall be paid to Employee&#146;s devisee, legatee, or other designee or, if there is no such designee, Employee&#146;s estate.
This Agreement shall be for the benefit of and binding upon the parties hereto and their respective heirs, personal representatives, legal representatives, successors and, where applicable, assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signatures on following page</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Agreement has been executed by the Parties as of the dates
set forth below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EMPLOYER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDNAX SERVICES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Manuel Kadre</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manuel Kadre</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lead Independent Director, MEDNAX, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>July&nbsp;12, 2020</U></TD></TR>
</TABLE> </DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>EMPLOYEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Roger J. Medel, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">ROGER J. MEDEL, M.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:&nbsp;&nbsp;&nbsp;&nbsp;<U>July&nbsp;12, 2020</U></TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to
Separation Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RELEASE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Release
(the &#147;Release&#148;) is hereby made and entered into between MEDNAX SERVICES, INC. (&#147;Employer&#148;) and ROGER J. MEDEL, M.D. (&#147;Employee&#148;) to be effective as set forth in Section&nbsp;10 below. Employee&#146;s execution of this
Release is a condition to his receipt of the benefits pursuant to Section&nbsp;2 and Section&nbsp;3 of the Separation Agreement between Employer and Employee effective as of July&nbsp;12, 2020 (the &#147;Agreement&#148;), to which this Release is
attached as Exhibit A. Any terms not defined herein shall have the meaning set forth in the Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Release</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Employee, for himself and his family, heirs, executors, administrators, legal representatives, and their respective
successors and assigns, in exchange for the consideration to be provided pursuant to Article 5 of the Employment Agreement and as set forth in Sections <FONT STYLE="white-space:nowrap">2-3</FONT> of the Agreement hereby gives up, releases, and
discharges Employer, MEDNAX, Inc. and each of their subsidiaries, Affiliates, successors and assigns, and their current and former directors, managers, officers, employees, shareholders and agents in such capacities (each a &#147;Released
Party&#148; and, collectively with Employer and MEDNAX, Inc., the &#147;Released Parties&#148;) from any and all rights and claims that Employee may have against the Released Parties as of the date Employee signs this Release arising from or in
connection with Employee&#146;s employment or termination of employment with Employer, including without limitation any and all rights and claims to or for attorneys&#146; fees, whether or not Employee presently is aware of such rights or claims or
suspects them to exist. These rights and claims include, but are not limited to, any and all rights and claims which Employee may have under, or arising out of, the Age Discrimination in Employment Act of 1967, as amended (the &#147;ADEA&#148;); the
Americans with Disabilities Act of 1990, as amended; the Family and Medical Leave Act; Title VII of the Civil Rights Act of 1964, as amended; and any other federal, state, or local constitution, statute, ordinance, executive order, or common law.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in Paragraph 1(a) above to the contrary, this Release shall not apply to (i)&nbsp;any
actions to enforce rights to receive any payments or benefits which may be due to Employee pursuant to the Employment Agreement, under any of Employer&#146;s employee benefit plans, or the Consulting Agreement; (ii)&nbsp;any rights or claims that
may arise as a result of events occurring after the date this Release is signed by Employee; (iii)&nbsp;any indemnification rights Employee may have as a current or former officer or director of Employer or its Affiliates; (iv)&nbsp;any claims for
benefits under any directors&#146; or officers&#146; liability policy maintained by Employer or its Affiliates in accordance with the terms of such policy; (v)&nbsp;any rights Employee may have as a holder of equity securities of MEDNAX, including
all vesting and accelerated vesting rights as set forth in the Employment Agreement and the Agreement; (vi)&nbsp;any claims that cannot be waived as a matter of law; (vii)&nbsp;any claims Employee may have to government-sponsored and administered
benefits such as unemployment insurance, workers&#146; compensation insurance (excluding claims for retaliation under workers&#146; compensation laws), state disability insurance, and paid family leave benefits; and (viii)&nbsp;any benefits that
vested on or prior to the Separation Date pursuant to a written benefit plan sponsored by Employer and governed by the federal law known as &#147;ERISA.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Nothing in this Release prohibits or prevents Employee from
filing a charge with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before the U.S. Equal Employment Opportunity Commission, the National Labor Relations Board or a similar agency enforcing federal,
state or local anti-discrimination laws (except that Employee acknowledges that he may not recover any monetary benefits or personal relief in connection therewith). Additionally, nothing in this Release prevents Employee from: (i)&nbsp;reporting
possible violations of federal law or regulations, including any possible securities laws violations, to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the
U.S. Congress, or any agency Inspector General; (ii)&nbsp;making any other disclosures that are protected under the whistleblower provisions of federal law or regulations; or (iii)&nbsp;otherwise fully participating in any federal whistleblower
programs, including but not limited to any such programs managed by the U.S. Securities and Exchange Commission and/or the Occupational Safety and Health Administration.&nbsp;Moreover, nothing in this Release prohibits or prevents Employee from
receiving individual monetary awards or other individual relief by virtue of participating in such&nbsp;federal&nbsp;whistleblower programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Representations and Covenant Not to Sue</U>. Employee represents that he has not filed against the
Released Parties any complaints, charges, or lawsuits arising out of his employment, termination of employment, or any other matter arising on or prior to the date Employee signed this Release, and covenants and agrees that he will never
individually or with any person or entity file, or commence the filing of, any charge, lawsuit, complaint, or proceeding with any governmental agency, or against the Released Parties with respect to any of the matters released by Employee pursuant
to Paragraph 1(a) hereof (a &#147;Proceeding&#148;); <U>provided</U>, <U>however</U>, Employee retains the right to commence a Proceeding to challenge whether Employee knowingly and voluntarily waived his rights under ADEA. If Employee does pursue a
legal claim or files an administrative charge that may not be released as a matter of law, or if such a claim or charge is brought on Employee&#146;s behalf, Employee waives any right to recover any monetary payments or other individual benefits in
any such proceeding (except that, for purposes of clarity, this limitation on monetary recovery shall not apply to proceedings before the Securities and Exchange Commission or pursuant to other federal whistleblower claims). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Reimbursements; Employee Acknowledgements</U>. Employee acknowledges that he has been or will be reimbursed by
Employer for all business expenses in accordance with Section&nbsp;3.1 of the Employment Agreement. Any requests for reimbursement of expenses must be submitted by September&nbsp;1, 2020 to the Chief Financial Officer of Employer and supported by
adequate documentation. Employee further acknowledges that he (a)&nbsp;has received payment in full for all services rendered in conjunction with Employee&#146;s employment by Employer and that no other compensation is owed to Employee except as
provided in the Agreement; (b)&nbsp;Employee has not been denied any request for leave to which he believes he was legally entitled, and Employee was not otherwise deprived of any of his rights under the Family and Medical Leave Act or any similar
state or local statute; and (c)&nbsp;Employee has not assigned or transferred, or purported to assign or transfer, to any person, entity, or individual whatsoever, any of the claims released in the foregoing general release and waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Return of Employer Property</U>. Employee agrees that, in accordance with Section&nbsp;8.4 of the Employment
Agreement, he has returned all Employer Property (as defined in Section 8.4 of the Employment Agreement) that Employer has requested he return and that he will return any unreturned Employer Property promptly upon Employer&#146;s request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Separation Agreement</U>. This Release incorporates by
reference, as if set forth fully herein, all terms and conditions of the Agreement. Employee acknowledges that this Release is not intended to otherwise change, alter or amend any of the terms and conditions of the Agreement, which Agreement remains
in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If any provision of this Agreement, or any part thereof, is
determined to be invalid or unenforceable by a court having jurisdiction in the matter, all of the remaining provisions and parts of this Agreement shall remain fully enforceable; except that, if the provisions in Paragraph 1 concerning releases are
held to be invalid, illegal, or unenforceable, then Employee will be required to enter into a new Release with an enforceable release, unless otherwise agreed to in writing by all parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consideration Period; Revocation Period</U>. Employee hereby shall have
<FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days to sign this Release, but he may knowingly and voluntarily waive that <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;day period by signing this Release earlier. Employee
shall have seven (7)&nbsp;days following the date on which he signs this Release within which he may revoke it by providing a written notice of his revocation to the General Counsel of Employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Employee Acknowledgement</U>. Employee acknowledges that he has read this Release, that he has been
advised to consult with an attorney before he signs this Release, and that he understands all of its terms and signs it voluntarily and with full knowledge of its significance and the consequences thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consideration</U>. Employee acknowledges that the execution of this Release is in further consideration of the
payments due to Employee under the Consulting Agreement and as set forth in Section&nbsp;3 of the Agreement, which includes benefits to which Employee acknowledges he would not be entitled if he did not sign this Release </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective Date</U>. This Release shall take effect on the eighth (8th) day following Employee&#146;s signing it
unless Employee&#146;s written revocation is delivered to the General Counsel of Employer within seven (7)&nbsp;days after Employee signs this Release, in which case this Release shall be null and void and of no legal effect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee provides this Release as of the current date. Employee intends that this Release become a binding agreement between Employee and Employer.
</I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signatures on following page</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EMPLOYER:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDNAX SERVICES, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Manuel Kadre</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">Manuel Kadre</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Lead Independent Director, MEDNAX, Inc.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><U>July&nbsp;12, 2020</U></TD></TR></TABLE>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;
</P></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>EMPLOYEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Roger J. Medel, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">ROGER J. MEDEL, M.D.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:&nbsp;&nbsp;&nbsp;&nbsp;<U>July&nbsp;12, 2020</U></TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Release]
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSULTING AGREEMENT </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSULTING AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS CONSULTING AGREEMENT</B> (this &#147;Agreement&#148;) is effective as of the Effective Date set forth herein by and between <B>Roger
J. Medel, M.D.</B> (hereinafter referred to as &#147;Contractor&#148;) and <B>MEDNAX SERVICES, INC., </B>a corporation organized pursuant to the laws of the State of Florida (hereinafter referred to as &#147;MEDNAX&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> MEDNAX provides management services to practices that service patients in the medical specialties of neonatology, pediatrics,
maternal-fetal medicine, radiology, teleradiology and other related specialties; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS,</B> the parties have executed a Separation
Agreement of even date (the &#147;Separation Agreement&#148;), which provides for Contractor to provide post-separation consulting services to MEDNAX pursuant to this Agreement; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>Contractor has expertise and knowledge relevant to MEDNAX&#146;s business and can provide assistance to MEDNAX in his area of
expertise; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS, </B>MEDNAX desires to engage Contractor and Contractor desires to provide the Services (as defined below) to
MEDNAX pursuant to the terms of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE</B>, in consideration of the mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties, intending to be legally bound, hereby agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Independent Contractor Relationship</U></B>. MEDNAX hereby contracts with Contractor and Contractor hereby accepts such
independent contractor status to perform the Services for MEDNAX upon the terms and conditions hereinafter set forth. Nothing contained herein is intended to create, nor shall this Agreement be construed as creating, a relationship of
employer-employee, principal-agent, or partnership between the parties. The manner and means by which Contractor chooses to complete the Services are in Contractor&#146;s sole discretion and control. Contractor is not authorized to make any
representation, contract, or commitment on behalf of MEDNAX or incur any liabilities or obligations of any kind in the name of or on behalf of MEDNAX. Any persons employed by or subcontracting with Contractor to perform any part of Contractor&#146;s
obligations hereunder shall be under the sole control and direction of Contractor and Contractor shall be solely responsible for all liabilities and expenses thereof. MEDNAX shall have no right or authority with respect to the selection, control,
direction, or compensation of such persons. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>II.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Duties and Services to be Provided by Contractor</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Duties</U></B>. It is understood and agreed that in the performance of the Services, duties and
obligations set forth in this Agreement, Contractor shall at all times be acting and performing as an independent contractor. The duties of Contractor shall be to provide advisory and consulting services in Contractor&#146;s area of expertise as
agreed between Contractor and the Board of Directors of MEDNAX, Inc. (the &#147;Board&#148;) or the Chief Executive Officer of MEDNAX (the Board and the Chief Executive Officer, each a Responsible Party and, collectively, the &#147;Responsible
Parties&#148;). The duties of Contractor shall include, but not be limited to, the following, in each case as agreed by Contractor and a Responsible Party: (i)&nbsp;performing activities to promote MEDNAX&#146;s business, (ii)&nbsp;providing
transition briefing information to MEDNAX&#146;s executives and officers with respect to any and all operational matters and plans in which Contractor was involved during his position </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as an officer of MEDNAX, for which Contractor was responsible during his position as an officer of MEDNAX, or about which Contractor has knowledge as a result of his former role as an officer of
MEDNAX, and (iii)&nbsp;performing other services to effect an orderly and professional transition of Contractor&#146;s former job duties and responsibilities (the duties described above and in clauses&nbsp;(i) through (iii)&nbsp;are referred to as
the &#147;Services&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Scheduling of Services</U></B>. Contractor shall work a schedule as
agreed with the Responsible Parties. Contractor shall render services hereunder at Contractor&#146;s offices with occasional travel based on the nature of the projects, except that Contractor shall be expected to attend meetings of the Board.
Contractor&#146;s primary contact for the scheduling of the Services shall be Dominic Andreano, General Counsel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Covenants and Representations</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C.1.&nbsp;&nbsp;&nbsp;&nbsp;Contractor agrees to (i)&nbsp;perform the Services in a reasonable, professional manner at all times and in
accordance with standard applicable policies and procedures of MEDNAX; and (ii)&nbsp;to comply with the provisions of all state, local, and federal laws, regulations, ordinances, requirements and codes which are applicable to the performance of the
Services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C.2.&nbsp;&nbsp;&nbsp;&nbsp;Upon execution of an appropriate &#147;Terms of Use Agreement&#148;, Contractor will be provided
access free of charge to MEDNAX&#146;s computer network. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">C.3.&nbsp;&nbsp;&nbsp;&nbsp;MEDNAX agrees to make available to Contractor all
necessary records, reports, or other information in the custody of MEDNAX or its related practice groups, including, but not limited, to electronic mail and any and all internal documents and any and all external documents reasonably needed&nbsp;for
performing the Services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>III.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Compensation</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Fee</U></B>. For all Services rendered by Contractor pursuant to this Agreement, Contractor shall
receive a consulting fee equal to One Hundred Seventy-Seven Thousand Eighty-Three Dollars and Thirty-Three Cents ($177,083.33) per month (the &#147;Fee&#148;). The Fee shall be paid to Contractor by MEDNAX on a monthly basis in arrears no later than
the fifth business day of each month for Services rendered during the immediately preceding month. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Expenses</U></B>. Contractor shall be reimbursed for ordinary and necessary expenses incurred by
Contractor in the performance of Services that have been expressly approved in advance by MEDNAX, provided that Contractor has furnished such documentation for authorized expenses as MEDNAX may reasonably request. Contractor shall submit written
documentation and receipts where available, itemizing the dates on which expenses are incurred. MEDNAX shall pay Contractor the amounts due pursuant to submitted reports. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Other</U></B>. As an independent contractor, Contractor understands that Contractor shall be fully
responsible for Contractor&#146;s own self-employment tax payments, as well as Social Security and other required tax payments. In addition, Contractor shall be responsible for Contractor&#146;s own benefits, including health insurance coverage,
disability insurance coverage, life insurance coverage, any other insurance and retirement plan, except as set forth in the Separation Agreement. MEDNAX shall only be responsible for payment of the Fee and travel expenses listed
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in Section III.A. and Section III.B above. With respect to payments for premiums/deductibles, taxes, and withholdings described herein, Contractor shall indemnify and hold MEDNAX harmless from
and against any and all claims, damages, losses or obligations asserted or imposed against MEDNAX by any local, state or federal agency or any other person or entity in connection with payment or recovery of such sums. MEDNAX shall provide
Contractor with Form 1099 as required by law, showing all payments to Contractor for services rendered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>IV.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Term and
Termination</U></B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Term and Termination.</U></B> The term of this Agreement shall commence on
July&nbsp;12, 2020, provided that the Separation Agreement becomes effective according to its terms (the &#147;Effective Date&#148;), and end on the first anniversary of the Effective Date (the &#147;Term&#148;), unless this Agreement is earlier
terminated as provided below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination by Contractor</U></B>. Contractor may terminate this
Agreement upon at least thirty (30)&nbsp;days prior written notice to MEDNAX. In the event of a termination set forth in this Section IV.B, MEDNAX shall (i)&nbsp;pay Contractor all monies due through the date of termination and (ii)&nbsp;reimburse
the Contractor for <FONT STYLE="white-space:nowrap">non-cancellable</FONT> expenses incurred hereunder prior to the date of notice of termination. As of the termination date or such earlier date at the direction of MEDNAX, Contractor shall stop all
work under this Agreement and incur no further expenses hereunder. Contractor shall not receive any additional Fees or other compensation as of the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination by MEDNAX for Breach</U></B>. MEDNAX may terminate this Agreement immediately upon the
Contractor&#146;s revocation of the Separation Agreement, Contractor&#146;s willful refusal to perform the Services pursuant to this Agreement, or Contractor&#146;s Material Breach. The term &#147;Material Breach&#148; shall mean the occurrence of
any of (i)&nbsp;Contractor&#146;s engagement in (a)&nbsp;willful misconduct resulting in material harm to Mednax, or (b)&nbsp;gross negligence; (ii)&nbsp;Contractor&#146;s conviction of, or pleading nolo contendere to, a felony or any other crime
involving fraud, financial misconduct, or misappropriation of Mednax&#146; assets; (iii)&nbsp;Contractor&#146;s willful and continual failure, after written notice from the Board to (a)&nbsp;perform substantially the Services, or (b)&nbsp;follow,
consistent with the Services, the reasonable lawful mandates of the Board; or (iv)&nbsp;Contractor&#146;s material breach of the Separation Agreement (including the documents referenced therein).&nbsp;&nbsp;&nbsp;&nbsp;No act or omission shall be
deemed willful or grossly negligent for purposes of this definition if taken or omitted to be taken by Contractor in a good faith belief that such act or omission to act was in the best interests of Mednax or if done at the express direction of the
Board. In the event of a termination set forth in this Section IV.C, MEDNAX shall (x)&nbsp;promptly pay Contractor all monies due through the date of notice of termination and (y)&nbsp;reimburse the Contractor for
<FONT STYLE="white-space:nowrap">non-cancellable</FONT> expenses incurred hereunder prior to the date of notice of termination. Upon the notice of termination, Contractor shall stop all work under this Agreement and incur no further expenses
hereunder. Contractor shall not receive any additional Fees or other compensation as of the date of termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Termination by MEDNAX for Convenience</U></B>. In addition to the termination rights set forth in
Section IV.C, MEDNAX may terminate this Agreement for any other reason upon at least thirty (30)&nbsp;days prior written notice to Contractor. In the event of a termination set forth in this Section IV.D, MEDNAX shall (i)&nbsp;pay Contractor a lump
sum payment equal to the unpaid </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Fees for each month remaining in the Term, payable no later than the date of termination; and (ii)&nbsp;reimburse the Contractor for <FONT STYLE="white-space:nowrap">non-cancellable</FONT>
expenses incurred hereunder prior to the date of notice of termination. Upon the notice of termination, the Contractor shall stop all work under this Agreement and incur no further expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>V.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Confidential Information; Intellectual Property Ownership</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Confidential Information</U></B>. Section&nbsp;8.4 (Confidential Information) of that certain
Employment Agreement, dated August&nbsp;7, 2011, by and between MEDNAX and Consultant, as amended (the &#147;Employment Agreement&#148;) is hereby incorporated by reference in this Agreement, <I>mutatis mutandis</I>, and shall apply during the Term
such that if Contractor receives access to any information in the course of providing Services during the Term that would have been &#147;Confidential Information&#148; (as defined in the Employment Agreement) if Contractor received access to such
information during the term of the Employment Agreement, then any such information shall be deemed &#147;Confidential Information&#148; (as defined in the Employment Agreement) and the provision in Section&nbsp;8.4 of the Employment Agreement shall
apply to such information. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section&nbsp;1833(b), Contractor shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is
made: (i)&nbsp;in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation of law; or (ii)&nbsp;in a complaint or
other document filed in a lawsuit or other proceeding, if such filing is made under seal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Ownership of Work Product</U></B><B>. </B>Section&nbsp;8.5 (Ownership of Work Product) of the
Employment Agreement is hereby incorporated by reference in this Agreement, <I>mutatis mutandis</I>, and shall apply during the Term such that if Contractor conceives creates, designs, develops, or contributes any work product in the course of
providing Services during the Term that would have been a &#147;Work Product&#148; (as defined in the Employment Agreement) if Contractor had conceived, created, designed, developed, or contributed such work product during the term of the Employment
Agreement, then any such work product shall be deemed a &#147;Work Product&#148; (as defined in the Employment Agreement) and the provision in Section&nbsp;8.5 of the Employment Agreement shall apply to such work product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Survival</U></B>. The provisions of this Section VI shall survive the termination of this Agreement and
Contractor&#146;s services with MEDNAX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>VI.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Miscellaneous</U></B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Notices</U></B>. Any notice required or permitted to be given under this Agreement shall be in writing
and shall be deemed to have been properly delivered, given and received (i)&nbsp;on the date of delivery if delivered by hand during normal business hours of the recipient during a business day, otherwise on the next business day, (ii)&nbsp;on the
date of transmission if an executed copy of such notice is sent via email with receipt acknowledged, or (iii)&nbsp;on the date of receipt by the addressee if sent by a nationally recognized overnight courier or by registered or certified mail,
return receipt requested, if received on a business day, otherwise on the next business day, at the address set forth below (or at such other address as shall be specified by a party in a notice given in accordance with this Section VII.A): </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="79%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">To&nbsp;MEDNAX:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX Services, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Legal Department</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1301 Concord Terrace</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sunrise, FL 33323-2825</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To Contractor:</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">With a copy, which shall not constitute notice, to:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roger J. Medel, M.D.</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brett Hendee</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hendee, McKernan, Schroeder,</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Wilkerson&nbsp;&amp; Hendee,
P.A.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1700 South MacDill Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 200</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Tampa, FL 33629</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Modification</U></B>. This Agreement shall not be changed,
modified or amended in any respect except by a written instrument signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>C.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Choice of Law and Invalid Provisions</U></B>. This Agreement shall be governed by and construed in
accordance with the laws of the State of Florida without regard to its conflict of laws principles to the extent that such principles would require the application of laws other than the laws of the State of Florida. Any dispute between the parties
related to this Agreement shall be determined according to the arbitration and dispute resolution provisions set forth in Section&nbsp;9 of the Employment Agreement, as amended by the Separation Agreement, which provisions are incorporated by
reference in this Agreement, <I>mutatis mutandis</I>. Nothing contained herein shall be construed to prevent MEDNAX or Consultant from seeking and recovering from the other damages sustained by either or both of them as a result of a breach of any
term or provision of this Agreement. In the event of any controversy or claim arising out of or relating to this Agreement, each party will bear its own costs for arbitration or court and attorneys&#146; fees. The invalidity of any one or more of
the words, phrases, sentences, clauses or Sections contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>D.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Successors</U></B>. MEDNAX shall require any successor (whether direct or indirect, by purchase,
merger, consolidation or otherwise) acquiring a majority of MEDNAX, Inc.&#146;s voting common stock or any other successor to all or substantially all of the business and/or assets of MEDNAX, Inc. to expressly assume and agree to perform and cause
MEDNAX to perform this Agreement in the same manner and to the same extent that MEDNAX would be required to perform it if no such succession had taken place and Consultant hereby consents to any such assignment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>E.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Assignment; Third Party Beneficiaries</U></B>. This Agreement and all rights of Consultant under this
Agreement shall inure to the benefit of and be enforceable by Consultant&#146;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Consultant should die after the Term and amounts
would have been payable to Consultant under this Agreement if Consultant had continued to live, then such amounts </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shall be paid to Consultant&#146;s devisee, legatee, or other designee or, if there is no such designee, Consultant&#146;s estate. This Agreement shall be for the benefit of and binding upon the
parties hereto and their respective heirs, personal representatives, legal representatives, successors and, where applicable, assigns. Notwithstanding the foregoing, Consultant may not assign the rights or benefits hereunder without the prior
written consent of MEDNAX. Nothing expressed or implied in this Agreement is intended, or shall be construed, to confer upon or give any person (other than the parties hereto and, in the case of Consultant, Consultant&#146;s heirs, personal
representative(s) and/or legal representative) any rights or remedies under or by reason of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Waiver</U></B>. The waiver by either party hereto of a breach or violation of any term or provision of
this Agreement shall not operate nor be construed as a waiver of any subsequent breach or violation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>G.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B><U>Entire Agreement</U></B>. This Agreement, together with the Separation Agreement and the other
documents referenced therein, constitutes the entire agreement between the parties with respect to its subject matter and supersedes any and all prior agreements, arrangements or understandings, written or oral, between the parties with respect to
the same subject matter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[signature page to follow] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Agreement has been executed by the parties as of the
Effective Date set forth herein. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX SERVICES, INC.</B></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> </DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>CONTRACTOR:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><B>ROGER J. MEDEL, M.D.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD></TR>
</TABLE> </div><div style="clear:both; height:0pt; font-size:0pt">&nbsp;</div>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>d82405dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDMENT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>SECOND AMENDMENT TO </B><B>AMENDED AND RESTATED</B> <B>EMPLOYMENT AGREEMENT</B> (the &#147;Amendment&#148;) is entered into by and
between <B>MEDNAX SERVICES, INC.</B>, a Florida corporation (&#147;Employer&#148;), and&nbsp;Stephen D. Farber&nbsp;(&#147;Employee&#148;) on July&nbsp;12, 2020, and shall be effective as such date (&#147;Effective Date&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
Employer and Employee are the parties to that certain Amended and Restated Employment Agreement, effective as of February&nbsp;13, 2020, as amended by that certain First Amendment to Amended and Restated Employment Agreement, effective April&nbsp;1,
2020 (collectively, the &#147;Employment Agreement&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Employer acknowledges that Employee has the basis to terminate
Employee&#146;s employment for &#147;Good Reason&#148; pursuant to Section&nbsp;4.7 of the Employment Agreement as a result of Roger J. Medel, M.D. no longer being the senior most executive officer of MEDNAX; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in the event that Employee terminates Employee&#146;s employment for &#147;Good Reason&#148; pursuant to Section&nbsp;4.7 of
the Employment Agreement, Employee is entitled to certain severance benefits, including the accelerated vesting of all Equity Awards granted to Employee by MEDNAX prior to the Effective Date, in each case subject to the terms of the Employment
Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in exchange for Employer&#146;s agreement to amend the Employment Agreement as provided in this Amendment,
Employee agrees not to provide written notice of termination of Employee&#146;s employment under the Agreement for &#147;Good Reason&#148; prior to the sixtieth (60th) day after the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> in consideration of the mutual promises and covenants contained herein, Employer and Employee agree to the following:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;All capitalized terms used but not otherwise defined in this Amendment have the meanings provided in the
Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>&nbsp;&nbsp;&nbsp;&nbsp;Employee agrees not to provide Employer with written notice of termination of
Employee&#146;s employment under the Agreement for &#147;Good Reason&#148; as contemplated by Section&nbsp;4.7 of the Employment Agreement prior to the sixtieth (60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after the Effective
Date. Employee further agrees that if Employee elects to terminate Employee&#146;s employment on or after the sixtieth (60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after the Effective Date for &#147;Good Reason&#148; as a result
of Roger J. Medel, M.D. no longer being the senior most executive officer of MEDNAX, then the effective date of such termination shall be the thirtieth (30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after the date of Employee&#146;s
notice of termination, <I>provided</I>, <I>however</I>, Employer may, at its option, require Employee to terminate employment at any time in advance of the expiration of such thirty (30)&nbsp;day period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>&nbsp;&nbsp;&nbsp;&nbsp;The first sentence of Section&nbsp;4.1 of the Employment Agreement is hereby deleted in its entirety and
replaced with the following: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Employer may terminate Employee&#146;s employment under this Agreement for Cause,
except during the <FONT STYLE="white-space:nowrap">ninety-one</FONT> (91)&nbsp;day period beginning on the Effective Date of the Second Amendment to this Agreement.&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any contrary provision in the Employment Agreement or&nbsp;any Equity Plan then maintained by
MEDNAX, and in addition to any other payments or benefits provided in Article 5 of the Employment Agreement upon a termination of Employee&#146;s employment pursuant to Section&nbsp;4.7 of the Employment Agreement, all Equity Awards granted to
Employee by MEDNAX prior to the Effective Date shall become fully <FONT STYLE="white-space:nowrap">vested,&nbsp;non-forfeitable,&nbsp;and,</FONT> if applicable, exercisable as of the Effective Date, subject to Employee&#146;s timely execution and <FONT
STYLE="white-space:nowrap">non-revocation</FONT> of the general release to the Amendment as Exhibit A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>&nbsp;&nbsp;&nbsp;&nbsp;Except as specifically amended hereby, the Employment Agreement is and remains unmodified and in full force
and effect and is hereby ratified and confirmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B>&nbsp;&nbsp;&nbsp;&nbsp;This Amendment shall be governed by and construed in
accordance with the terms and conditions of the Employment Agreement, including the governing law and dispute resolution provisions thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;This Amendment may be executed in counterparts and both of such counterparts shall for all purposes be deemed
to be an original, and such counterparts shall constitute one and the same instrument. The Amendment may be executed by facsimile or other electronic signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally left blank; signatures follow on next page] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned have executed this Amendment as of the Effective
Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX SERVICES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cesar L. Alvarez</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Cesar L. Alvarez</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: Chairman of the Board,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>MEDNAX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cesar L. Alvarez</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Cesar L. Alvarez</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: Chairman of the Board</P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>EMPLOYEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen D. Farber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Stephen D. Farber</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second Amendment to Employment Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RELEASE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Release
(the &#147;Release&#148;) is hereby made and entered into between MEDNAX SERVICES, INC. (&#147;Employer&#148;) and Stephen D. Farber (&#147;Employee&#148;) to be effective as set forth in Section&nbsp;7 below. Employee&#146;s execution of this
Release is a condition to his receipt of the benefits pursuant to Section&nbsp;4 of the Second Amendment to the Employment Agreement between Employer and Employee effective as of July&nbsp;12, 2020 (the &#147;Amendment&#148;), to which this Release
is attached as Exhibit A. Any terms not defined herein shall have the meaning set forth in the Amendment or the Employment Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Release</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Employee, for himself and his family, heirs, executors, administrators, legal representatives, and their respective
successors and assigns, in exchange for the consideration to be provided pursuant to Section&nbsp;4 of the Amendment hereby gives up, releases, and discharges Employer, MEDNAX, Inc. and each of their subsidiaries, Affiliates, successors and assigns,
and their current and former directors, managers, officers, employees, shareholders and agents in such capacities (each a &#147;Released Party&#148; and, collectively with Employer and MEDNAX, Inc., the &#147;Released Parties&#148;) from any and all
rights and claims that Employee may have against the Released Parties as of the date Employee signs this Release arising from or in connection with Employee&#146;s employment with Employer, including without limitation any and all rights and claims
to or for attorneys&#146; fees, whether or not Employee presently is aware of such rights or claims or suspects them to exist. These rights and claims include, but are not limited to, any and all rights and claims which Employee may have under, or
arising out of, the Age Discrimination in Employment Act of 1967, as amended (the &#147;ADEA&#148;); the Americans with Disabilities Act of 1990, as amended; the Family and Medical Leave Act; Title VII of the Civil Rights Act of 1964, as amended;
and any other federal, state, or local constitution, statute, ordinance, executive order, or common law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in Paragraph 1(a) above to the contrary, this Release shall not apply to (i)&nbsp;any
actions to enforce rights to receive any payments or benefits which may be due to Employee pursuant to the Employment Agreement or under any of Employer&#146;s employee benefit plans; (ii)&nbsp;any rights or claims that may arise as a result of
events occurring after the date this Release is signed by Employee; (iii)&nbsp;any indemnification rights Employee may have as a current or former officer or director of Employer or its Affiliates; (iv)&nbsp;any claims for benefits under any
directors&#146; or officers&#146; liability policy maintained by Employer or its Affiliates in accordance with the terms of such policy; (v)&nbsp;any rights Employee may have as a holder of equity securities of MEDNAX, including all vesting and
accelerated vesting rights as set forth in the Employment Agreement; (vi)&nbsp;any claims that cannot be waived as a matter of law; (vii)&nbsp;any claims Employee may have to government-sponsored and administered benefits such as unemployment
insurance, workers&#146; compensation insurance (excluding claims for retaliation under workers&#146; compensation laws), state disability insurance, and paid family leave benefits; (viii)&nbsp;any benefits that vested on or prior to the Effective
Date pursuant to a written benefit plan sponsored by Employer and governed by the federal law known as &#147;ERISA&#148;; and (ix)&nbsp;any claims with respect to Employee&#146;s continued employment after the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Nothing in this Release prohibits or prevents Employee from
filing a charge with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before the U.S. Equal Employment Opportunity Commission, the National Labor Relations Board or a similar agency enforcing federal,
state or local anti-discrimination laws (except that Employee acknowledges that he may not recover any monetary benefits or personal relief in connection therewith). Additionally, nothing in this Release prevents Employee from: (i)&nbsp;reporting
possible violations of federal law or regulations, including any possible securities laws violations, to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the
U.S. Congress, or any agency Inspector General; (ii)&nbsp;making any other disclosures that are protected under the whistleblower provisions of federal law or regulations; or (iii)&nbsp;otherwise fully participating in any federal whistleblower
programs, including but not limited to any such programs managed by the U.S. Securities and Exchange Commission and/or the Occupational Safety and Health Administration.&nbsp;Moreover, nothing in this Release prohibits or prevents Employee from
receiving individual monetary awards or other individual relief by virtue of participating in such&nbsp;federal&nbsp;whistleblower programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Representations and Covenant Not to Sue</U>. Employee represents that he has not filed against the
Released Parties any complaints, charges, or lawsuits arising out of his employment, termination of employment, or any other matter arising on or prior to the date Employee signed this Release, and covenants and agrees that he will never
individually or with any person or entity file, or commence the filing of, any charge, lawsuit, complaint, or proceeding with any governmental agency, or against the Released Parties with respect to any of the matters released by Employee pursuant
to Paragraph 1(a) hereof (a &#147;Proceeding&#148;); <U>provided</U>, <U>however</U>, Employee retains the right to commence a Proceeding to challenge whether Employee knowingly and voluntarily waived his rights under ADEA. If Employee does pursue a
legal claim or files an administrative charge that may not be released as a matter of law, or if such a claim or charge is brought on Employee&#146;s behalf, Employee waives any right to recover any monetary payments or other individual benefits in
any such proceeding (except that, for purposes of clarity, this limitation on monetary recovery shall not apply to proceedings before the Securities and Exchange Commission or pursuant to other federal whistleblower claims). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If any provision of this Agreement, or any part thereof, is determined to be invalid or
unenforceable by a court having jurisdiction in the matter, all of the remaining provisions and parts of this Agreement shall remain fully enforceable; except that, if the provisions in Paragraph 1 concerning releases are held to be invalid,
illegal, or unenforceable, then Employee will be required to enter into a new Release with an enforceable release, unless otherwise agreed to in writing by all parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consideration Period; Revocation Period</U>. Employee hereby shall have
<FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days to sign this Release, but he may knowingly and voluntarily waive that <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;day period by signing this Release earlier. Employee
shall have seven (7)&nbsp;days following the date on which he signs this Release within which he may revoke it by providing a written notice of his revocation to the General Counsel of Employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Employee Acknowledgement</U>. Employee acknowledges that he has read this Release, that he has been
advised to consult with an attorney before he signs this Release, and that he understands all of its terms and signs it voluntarily and with full knowledge of its significance and the consequences thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consideration</U>. Employee acknowledges that the execution of
this Release is in further consideration of the payments due to Employee under Section&nbsp;4 of the Amendment, which includes benefits to which Employee acknowledges he would not be entitled if he did not sign this Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective Date</U>. This Release shall take effect on the eighth (8th) day following Employee&#146;s signing it
unless Employee&#146;s written revocation is delivered to the General Counsel of Employer within seven (7)&nbsp;days after Employee signs this Release, in which case this Release shall be null and void and of no legal effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee provides this Release as of the current date. Employee intends that this Release become a binding agreement between Employee and Employer.
</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>EMPLOYER:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>EMPLOYEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDNAX SERVICES, INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cesar L. Alvarez</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen D. Farber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Cesar L. Alvarez</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Stephen D. Farber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chairman of Board, MEDNAX, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">July&nbsp;12, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Date:&nbsp;&nbsp;&nbsp;&nbsp;July&nbsp;12, 2020</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>d82405dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><U>Execution Version </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND AMENDMENT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDED AND RESTATED EMPLOYMENT AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This <B>SECOND AMENDMENT TO </B><B>AMENDED AND RESTATED</B> <B>EMPLOYMENT AGREEMENT</B> (the &#147;Amendment&#148;) is entered into by and
between <B>MEDNAX SERVICES, INC.</B>, a Florida corporation (&#147;Employer&#148;), and&nbsp;Dominic J. Andreano&nbsp;(&#147;Employee&#148;) on July&nbsp;12, 2020, and shall be effective as such date (&#147;Effective Date&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>,
Employer and Employee are the parties to that certain Amended and Restated Employment Agreement, effective as of February&nbsp;13, 2020, as amended by that certain First Amendment to Amended and Restated Employment Agreement, effective April&nbsp;1,
2020 (collectively, the &#147;Employment Agreement&#148;); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, Employer acknowledges that Employee has the basis to terminate
Employee&#146;s employment for &#147;Good Reason&#148; pursuant to Section&nbsp;4.7 of the Employment Agreement as a result of Roger J. Medel, M.D. no longer being the senior most executive officer of MEDNAX; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in the event that Employee terminates Employee&#146;s employment for &#147;Good Reason&#148; pursuant to Section&nbsp;4.7 of
the Employment Agreement, Employee is entitled to certain severance benefits, including the accelerated vesting of all Equity Awards granted to Employee by MEDNAX prior to the Effective Date, in each case subject to the terms of the Employment
Agreement; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, in exchange for Employer&#146;s agreement to amend the Employment Agreement as provided in this Amendment,
Employee agrees not to provide written notice of termination of Employee&#146;s employment under the Agreement for &#147;Good Reason&#148; prior to the sixtieth (60th) day after the Effective Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW, THEREFORE,</B> in consideration of the mutual promises and covenants contained herein, Employer and Employee agree to the following:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;All capitalized terms used but not otherwise defined in this Amendment have the meanings provided in the
Employment Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B>&nbsp;&nbsp;&nbsp;&nbsp;Employee agrees not to provide Employer with written notice of termination of
Employee&#146;s employment under the Agreement for &#147;Good Reason&#148; as contemplated by Section&nbsp;4.7 of the Employment Agreement prior to the sixtieth (60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after the Effective
Date. Employee further agrees that if Employee elects to terminate Employee&#146;s employment on or after the sixtieth (60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after the Effective Date for &#147;Good Reason&#148; as a result
of Roger J. Medel, M.D. no longer being the senior most executive officer of MEDNAX, then the effective date of such termination shall be the thirtieth (30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after the date of Employee&#146;s
notice of termination, <I>provided</I>, <I>however</I>, Employer may, at its option, require Employee to terminate employment at any time in advance of the expiration of such thirty (30)&nbsp;day period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>&nbsp;&nbsp;&nbsp;&nbsp;The first sentence of Section&nbsp;4.1 of the Employment Agreement is hereby deleted in its entirety and
replaced with the following: </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">&#147;Employer may terminate Employee&#146;s employment under this Agreement for Cause,
except during the <FONT STYLE="white-space:nowrap">ninety-one</FONT> (91)&nbsp;day period beginning on the Effective Date of the Second Amendment to this Agreement.&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any contrary provision in the Employment Agreement or&nbsp;any Equity Plan then maintained by
MEDNAX, and in addition to any other payments or benefits provided in Article 5 of the Employment Agreement upon a termination of Employee&#146;s employment pursuant to Section&nbsp;4.7 of the Employment Agreement, all Equity Awards granted to
Employee by MEDNAX prior to the Effective Date shall become fully <FONT STYLE="white-space:nowrap">vested,&nbsp;non-forfeitable,&nbsp;and,</FONT> if applicable, exercisable as of the Effective Date, subject to Employee&#146;s timely execution and <FONT
STYLE="white-space:nowrap">non-revocation</FONT> of the general release to the Amendment as Exhibit A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>&nbsp;&nbsp;&nbsp;&nbsp;Except as specifically amended hereby, the Employment Agreement is and remains unmodified and in full force
and effect and is hereby ratified and confirmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B>&nbsp;&nbsp;&nbsp;&nbsp;This Amendment shall be governed by and construed in
accordance with the terms and conditions of the Employment Agreement, including the governing law and dispute resolution provisions thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;This Amendment may be executed in counterparts and both of such counterparts shall for all purposes be deemed
to be an original, and such counterparts shall constitute one and the same instrument. The Amendment may be executed by facsimile or other electronic signature. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally left blank; signatures follow on next page] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the undersigned have executed this Amendment as of the Effective
Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>MEDNAX SERVICES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cesar L. Alvarez</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Cesar L. Alvarez</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title: Chairman of the Board,</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>MEDNAX, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cesar L. Alvarez</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Name: Cesar L. Alvarez</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Title: Chairman of the Board</P></TD></TR>

<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>EMPLOYEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dominic J. Andreano</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Dominic J. Andreano</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Signature Page to Second Amendment to Employment Agreement] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT A </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RELEASE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Release
(the &#147;Release&#148;) is hereby made and entered into between MEDNAX SERVICES, INC. (&#147;Employer&#148;) and Dominic J. Andreano (&#147;Employee&#148;) to be effective as set forth in Section&nbsp;7 below. Employee&#146;s execution of this
Release is a condition to his receipt of the benefits pursuant to Section&nbsp;4 of the Second Amendment to the Employment Agreement between Employer and Employee effective as of July&nbsp;12, 2020 (the &#147;Amendment&#148;), to which this Release
is attached as Exhibit A. Any terms not defined herein shall have the meaning set forth in the Amendment or the Employment Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Release</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Employee, for himself and his family, heirs, executors, administrators, legal representatives, and their respective
successors and assigns, in exchange for the consideration to be provided pursuant to Section&nbsp;4 of the Amendment hereby gives up, releases, and discharges Employer, MEDNAX, Inc. and each of their subsidiaries, Affiliates, successors and assigns,
and their current and former directors, managers, officers, employees, shareholders and agents in such capacities (each a &#147;Released Party&#148; and, collectively with Employer and MEDNAX, Inc., the &#147;Released Parties&#148;) from any and all
rights and claims that Employee may have against the Released Parties as of the date Employee signs this Release arising from or in connection with Employee&#146;s employment with Employer, including without limitation any and all rights and claims
to or for attorneys&#146; fees, whether or not Employee presently is aware of such rights or claims or suspects them to exist. These rights and claims include, but are not limited to, any and all rights and claims which Employee may have under, or
arising out of, the Age Discrimination in Employment Act of 1967, as amended (the &#147;ADEA&#148;); the Americans with Disabilities Act of 1990, as amended; the Family and Medical Leave Act; Title VII of the Civil Rights Act of 1964, as amended;
and any other federal, state, or local constitution, statute, ordinance, executive order, or common law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything in Paragraph 1(a) above to the contrary, this Release shall not apply to (i)&nbsp;any
actions to enforce rights to receive any payments or benefits which may be due to Employee pursuant to the Employment Agreement or under any of Employer&#146;s employee benefit plans; (ii)&nbsp;any rights or claims that may arise as a result of
events occurring after the date this Release is signed by Employee; (iii)&nbsp;any indemnification rights Employee may have as a current or former officer or director of Employer or its Affiliates; (iv)&nbsp;any claims for benefits under any
directors&#146; or officers&#146; liability policy maintained by Employer or its Affiliates in accordance with the terms of such policy; (v)&nbsp;any rights Employee may have as a holder of equity securities of MEDNAX, including all vesting and
accelerated vesting rights as set forth in the Employment Agreement; (vi)&nbsp;any claims that cannot be waived as a matter of law; (vii)&nbsp;any claims Employee may have to government-sponsored and administered benefits such as unemployment
insurance, workers&#146; compensation insurance (excluding claims for retaliation under workers&#146; compensation laws), state disability insurance, and paid family leave benefits; (viii)&nbsp;any benefits that vested on or prior to the Effective
Date pursuant to a written benefit plan sponsored by Employer and governed by the federal law known as &#147;ERISA&#148;; and (ix)&nbsp;any claims with respect to Employee&#146;s continued employment after the Effective Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Nothing in this Release prohibits or prevents Employee from
filing a charge with or participating, testifying, or assisting in any investigation, hearing, or other proceeding before the U.S. Equal Employment Opportunity Commission, the National Labor Relations Board or a similar agency enforcing federal,
state or local anti-discrimination laws (except that Employee acknowledges that he may not recover any monetary benefits or personal relief in connection therewith). Additionally, nothing in this Release prevents Employee from: (i)&nbsp;reporting
possible violations of federal law or regulations, including any possible securities laws violations, to any governmental agency or entity, including but not limited to the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the
U.S. Congress, or any agency Inspector General; (ii)&nbsp;making any other disclosures that are protected under the whistleblower provisions of federal law or regulations; or (iii)&nbsp;otherwise fully participating in any federal whistleblower
programs, including but not limited to any such programs managed by the U.S. Securities and Exchange Commission and/or the Occupational Safety and Health Administration.&nbsp;Moreover, nothing in this Release prohibits or prevents Employee from
receiving individual monetary awards or other individual relief by virtue of participating in such&nbsp;federal&nbsp;whistleblower programs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Employee Representations and Covenant Not to Sue</U>. Employee represents that he has not filed against the
Released Parties any complaints, charges, or lawsuits arising out of his employment, termination of employment, or any other matter arising on or prior to the date Employee signed this Release, and covenants and agrees that he will never
individually or with any person or entity file, or commence the filing of, any charge, lawsuit, complaint, or proceeding with any governmental agency, or against the Released Parties with respect to any of the matters released by Employee pursuant
to Paragraph 1(a) hereof (a &#147;Proceeding&#148;); <U>provided</U>, <U>however</U>, Employee retains the right to commence a Proceeding to challenge whether Employee knowingly and voluntarily waived his rights under ADEA. If Employee does pursue a
legal claim or files an administrative charge that may not be released as a matter of law, or if such a claim or charge is brought on Employee&#146;s behalf, Employee waives any right to recover any monetary payments or other individual benefits in
any such proceeding (except that, for purposes of clarity, this limitation on monetary recovery shall not apply to proceedings before the Securities and Exchange Commission or pursuant to other federal whistleblower claims). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. If any provision of this Agreement, or any part thereof, is determined to be invalid or
unenforceable by a court having jurisdiction in the matter, all of the remaining provisions and parts of this Agreement shall remain fully enforceable; except that, if the provisions in Paragraph 1 concerning releases are held to be invalid,
illegal, or unenforceable, then Employee will be required to enter into a new Release with an enforceable release, unless otherwise agreed to in writing by all parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consideration Period; Revocation Period</U>. Employee hereby shall have
<FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days to sign this Release, but he may knowingly and voluntarily waive that <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;day period by signing this Release earlier. Employee
shall have seven (7)&nbsp;days following the date on which he signs this Release within which he may revoke it by providing a written notice of his revocation to the General Counsel of Employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional Employee Acknowledgement</U>. Employee acknowledges that he has read this Release, that he has been
advised to consult with an attorney before he signs this Release, and that he understands all of its terms and signs it voluntarily and with full knowledge of its significance and the consequences thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Consideration</U>. Employee acknowledges that the execution of
this Release is in further consideration of the payments due to Employee under Section&nbsp;4 of the Amendment, which includes benefits to which Employee acknowledges he would not be entitled if he did not sign this Release. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effective Date</U>. This Release shall take effect on the eighth (8th) day following Employee&#146;s signing it
unless Employee&#146;s written revocation is delivered to the Chief Financial Officer of Employer within seven (7)&nbsp;days after Employee signs this Release, in which case this Release shall be null and void and of no legal effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee provides this Release as of the current date. Employee intends that this Release become a binding agreement between Employee and Employer.
</I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="3"><B>EMPLOYER:</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>EMPLOYEE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MEDNAX SERVICES, INC.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By:</P> <P STYLE="font-size:1pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Cesar L. Alvarez</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dominic J. Andreano</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Cesar L. Alvarez</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Dominic J. Andreano</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chairman of Board, MEDNAX, Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">July&nbsp;12, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Date:&nbsp;&nbsp;&nbsp;&nbsp;July&nbsp;12, 2020</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>d82405dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g82405g0713074008037.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR MORE INFORMATION: &nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles Lynch&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Vice President,
Finance and Strategy&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">954-384-0175</FONT></FONT> ext.
5692&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>charles_lynch@mednax.com </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>FOR IMMEDIATE RELEASE </U></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MEDNAX
Announces Leadership and Board Transitions </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I> Mark S. Ordan Appointed Chief Executive Officer, Succeeding Company Founder Roger J.
Medel, M.D. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Guy P. Sansone Appointed Chair of Board of Directors </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Significant Board Refreshment, With Five New Independent Directors Appointed to Succeed Five Departing Directors </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Company Reaches Agreement with Starboard Value </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FORT LAUDERDALE, Fla.</B> &#151; July&nbsp;13, 2020 &#151; MEDNAX, Inc. (NYSE: MD), the nation&#146;s leading provider of maternal-fetal, newborn and
pediatric subspecialty care, today announced that the Company&#146;s Board of Directors has appointed Mark S. Ordan as Chief Executive Officer, succeeding Roger J. Medel, M.D., the Company&#146;s founder. Dr.&nbsp;Medel will remain a member of the
Board until the 2021 Annual Meeting of Shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Since founding this company in 1979, it has been my great honor and privilege to work
alongside MEDNAX&#146;s clinicians and employees over the past 41 years,&#148; said Dr.&nbsp;Medel. &#147;After four decades, I know that this organization&#146;s commitment to <I>Take Great Care of the Patient</I> is stronger than ever. I am
equally committed to ensuring a successful transition, and I am confident that we will touch even more lives and reach new heights for many years to come.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Ordan previously served as Chief Executive Officer of Quality Care Properties, Inc., a publicly traded real estate company and one of the largest
actively managed companies focused on post-acute, skilled nursing and memory care/assisted living properties, since its <FONT STYLE="white-space:nowrap">spin-off</FONT> from HCP, Inc. in 2016 until 2018. In July 2018, Mr.&nbsp;Ordan completed a sale
of the company to Welltower (NYSE: WELL) and Promedica. Mr.&nbsp;Ordan served as Chief Executive Officer of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Washington Prime Group Inc. (NYSE: WPG), a REIT that owns, develops and manages over 100 malls and shopping centers, from 2014 to 2015. During his tenure, he launched the company as a <FONT
STYLE="white-space:nowrap">spin-off</FONT> of the Simon Property Group (NYSE: SPG). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Ordan served as Chief Executive Officer of Sunrise Senior
Living, Inc., a publicly traded operator and owner of approximately 300 senior living communities in the United States, Canada and the United Kingdom, from 2008 to 2013. He led the turnaround and restructuring of Sunrise and oversaw the sale of the
company in January 2013 to Health Care REIT and KKR. Mr.&nbsp;Ordan served as Chief Executive Officer of The Mills Corporation, a publicly traded developer, owner and manager of a diversified portfolio of regional shopping malls and retail
entertainment centers, from 2006 to 2007. Mr.&nbsp;Ordan oversaw Mills&#146; operations and complete restructuring and led the Company&#146;s sale process to Simon Property Group and Farallon Capital Management, in May 2007. Mr.&nbsp;Ordan serves on
the Board of Directors of VEREIT (NYSE: VER) and Federal Realty Investment Trust (NYSE: FRT). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am honored to join MEDNAX&#146;s outstanding team
of passionate physicians, clinicians and employees,&#148; said Mr.&nbsp;Ordan. &#147;Roger is a renowned physician who has built an amazing company. I look forward to working with Guy, Roger, the other Board members and management team to continue
putting patient needs first and creating value for shareholders.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;On behalf of the entire Company, I want to thank Roger for his extraordinary
vision, leadership and contributions to MEDNAX throughout his decades of services as our CEO,&#148; said Manny Kadre, MEDNAX Lead Independent Director. &#147;Under his guidance and leadership, MEDNAX has grown from a single neonatology group into
the nationally recognized organization it is today. Since founding the Company, Roger has instilled a physician- and patient-centric culture that will endure for decades to come. We look forward to his continuing contributions as a member of our
Board of Directors.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors Transitions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company today also announced that its Board has appointed five new directors: Thomas A. McEachin, Mr.&nbsp;Ordan, Guy P. Sansone, John M. Starcher, Jr. and
Shirley A. Weis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commensurate with these appointments, current directors Cesar L. Alvarez, Michael B. Fernandez, Pascal J. Goldschmidt, M.D., Carlos A.
Migoya and Enrique J. Sosa, Ph.D. have stepped down from the Board. Mr.&nbsp;Sansone has succeeded Mr.&nbsp;Alvarez as Chair of the Board. These changes are effective immediately. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are excited to welcome Tom, Mark, Guy, John and Shirley to the MEDNAX Board of Directors,&#148; said Mr.&nbsp;Kadre. &#147;Together, these
experienced leaders possess deep collective knowledge of the healthcare services industry and I am confident that their unique expertise will further enhance the Board&#146;s capabilities to oversee the execution of the Company&#146;s strategy and
complete its transformation. I would also like to thank Cesar, Michael, Pascal, Carlos and Enrique for their deep dedication and exemplary service to MEDNAX over the years.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am proud to be joining the Board as Chair during such an exciting time for the Company,&#148; said
Mr.&nbsp;Sansone. &#147;I look forward to working with the Board and management team to help realize the remarkable future potential for this Company. I would like to thank Roger for building such an esteemed company, and I am confident that Mark is
the ideal leader to guide MEDNAX into its next chapter.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;MEDNAX is an outstanding company and I believe there is tremendous opportunity to
build upon the strong legacy and foundation that Roger has created,&#148; said Mr.&nbsp;Ordan. &#147;We will continue the Company&#146;s commitment to provide leading health solutions, deliver exceptional care for our patients, and improve patient
outcomes. Our strong network of experienced clinicians will continue to expand and evolve to meet our patients&#146; needs.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Agreement with
Starboard Value </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These announcements are pursuant to an agreement that MEDNAX has reached with Starboard Value LP and its affiliates
(&#147;Starboard&#148;), an investment firm which owns approximately 9.9% of MEDNAX&#146;s outstanding common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the agreement,
Starboard has withdrawn its director nominations previously submitted to the Company and agreed to support the Board&#146;s full slate of directors at the Company&#146;s 2020 Annual Meeting of Shareholders. Starboard also agreed to abide by
customary standstill provisions and voting commitments. The complete agreement will be filed by the Company with the U.S. Securities and Exchange Commission (&#147;SEC&#148;) as an exhibit to a Current Report on Form
<FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moelis&nbsp;&amp; Company and Barclays are serving as financial advisors and DLA Piper LLP (US) and Cleary
Gottlieb Steen&nbsp;&amp; Hamilton LLP are serving as legal counsel to MEDNAX. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Guy P. Sansone </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Sansone has served as the <FONT STYLE="white-space:nowrap">Co-Founder,</FONT> Chairman and Chief Executive Officer of H2 Health, a leading regional
provider of physical rehabilitation services and clinician staffing solutions, since February 2020. Prior to that, he served as Managing Director at Alvarez&nbsp;&amp; Marsal in New York, a financial advisory and consulting firm notable for its work
in turnaround management and performance improvement of a number of large, high-profile businesses across the globe, where he served as Chairman of the firm&#146;s Healthcare Industry Group, which he founded in 2004. Mr.&nbsp;Sansone has also served
on the Boards of Directors of Magellan Health, Inc. (NASDAQ: MGLN), a healthcare company focused on special populations, complete pharmacy benefits and other specialty areas of healthcare, since March 2019, and Carisk Partners, a risk transfer, care
coordination company, since April 2019, and as <FONT STYLE="white-space:nowrap">Non-Executive</FONT> Chairman of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Brookdale Senior Living, Inc. (NYSE: BKD), an owner and operator of senior living and retirement communities, since January 2020. Mr.&nbsp;Sansone has served on the Board of Advisors for Pager,
Inc., a mobile healthcare technology company, since March 2017. Previously, Mr.&nbsp;Sansone served on the Boards of Directors of Civitas Solutions, Inc. (formerly NYSE:CIVI), a leading national provider of
<FONT STYLE="white-space:nowrap">home-and</FONT> community-based health and human services to must-serve individuals with intellectual, developmental, physical or behavioral disabilities and other special needs, from December 2009 until its
acquisition by Celtic Intermediate Corp. in March 2019, and HealthPRO Heritage, a leading national provider of therapy management and consulting services, from September 2015 to November 2019. Over the past 20 years, he has invested in and consulted
as an executive to numerous companies, focusing on developing and evaluating strategic and operating alternatives designed to enhance value. Mr.&nbsp;Sansone earned a B.S. from the State University of New York at Albany. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Thomas A. McEachin </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;McEachin has served on
the Board of Directors of RTI Surgical Holdings, Inc. (NASDAQ: RTIX), a global implant company which designs, manufactures and distributes orthopedic and other surgical implants for use in various surgical procedures, since December 2015.
Previously, he held executive positions at Covidien Surgical Solutions, a division of Covidien plc (formerly NYSE: COV), a global health care products company and manufacturer of medical devices and supplies, from 2008 to 2012. During his tenure at
Covidien Surgical Solutions, he served as Vice President, Finance from 2008 to 2011 and Vice President and Group Chief Financial Officer from 2011 to 2012. From 1997 to 2008, Mr.&nbsp;McEachin served in various finance capacities at United
Technologies Corporation (NYSE: UTX), a global leader in the aerospace and building industries, and its subsidiaries, including as chief Investor Relations officer, Vice President and Controller of Pratt&nbsp;&amp; Whitney, and Vice President and
Chief Financial Officer of UTC Power. Prior to that, he held several executive positions with Digital Equipment Corporation (formerly NYSE: DEC), a vendor of computer systems, including computers, software, and peripherals, from 1986 to 1997.
Mr.&nbsp;McEachin was with Xerox Corporation (n/k/a Xerox Holdings Corporation) (NYSE: XRX), a global corporation that sells print and digital document products and services, from 1975 to 1986, serving as Controller of the procurement organization.
Mr.&nbsp;McEachin formerly served as a trustee and officer of the Wadsworth Atheneum (Hartford, CT), the oldest public art institution in the United States, serving on their executive, finance and investment committees. He also is a past board
member of the Connecticut Science Center and chair of the audit committee. Mr.&nbsp;McEachin holds a B.S. from New York University and an MBA from Stanford University. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About John M. Starcher, Jr. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Starcher is the
President and Chief Executive Officer of Bon Secours Mercy Health, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">not-for-profit</FONT></FONT> Catholic health system that owns and operates 48 acute care hospitals, over 1,000
sites of care serving more than 10&nbsp;million patients and has more than 60,000 employees across seven states and two countries, where he has served since September 2018. Prior to this, he served as
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Chief Executive Officer and President of Mercy Health from April 2016 to August 2018, where he oversaw the development of system strategies and operations for all 23 Mercy Health hospitals and
the clinically integrated network across Ohio and Kentucky. Before being promoted to Chief Executive Officer at Mercy Health, Mr.&nbsp;Starcher served as an Executive Vice President of Operations and Chief Executive Officer of the Cincinnati Market
at Mercy Health from January 2015 to April 2016. From August 2013 through March 2014, Mr.&nbsp;Starcher served as the Interim President and Chief Executive Officer of Health Management Associates Inc. (formerly NYSE: HMA) (&#147;HMA&#148;), an
integrated acute care delivery system with 71 hospitals across 15 states, where he guided HMA through its successful sale to Community Health Systems. Prior to that, Mr.&nbsp;Starcher served as President of HMA&#146;s Eastern Group from February
2012 until August 2013. Before joining HMA, Mr.&nbsp;Starcher served as the Chief Executive Officer of three of Mercy Health&#146;s four divisions &#150; overseeing more than 20 acute care hospitals, five long term care facilities, six home health
agencies and dozens of affiliated clinical practices with more than $3&nbsp;billion in net revenue. Prior to that, he served as the Chief Executive Officer of the Northeastern Pennsylvania Region, the senior vice president of Human Resources and
corporate associate general counsel at Catholic Health Partners. Mr.&nbsp;Starcher started his career in 1993 in Human Resources at the Medical College of Ohio as the Director of Labor Relations where he worked until he joined Catholic Health
Partners in 1999. Mr.&nbsp;Starcher serves as a Director on the Boards of Bon Secours Mercy Health, The Innovation Institute, the Catholic Medical Mission Board and American Pain Consortium, LLC. He also serves on the Advisory Board of HealthQuest
Capital. Mr.&nbsp;Starcher holds a Bachelor&#146;s degree in business administration from Bowling Green State University and a Doctorate in Jurisprudence from the University of Toledo. He is licensed to practice law in the State of Ohio (currently
inactive) and has actively served as a director on more than 20 boards in varied industries, including banking, insurance, acute and <FONT STYLE="white-space:nowrap">sub-acute</FONT> healthcare, specialty care and physician practice organizations.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Shirley A. Weis </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ms. Weis has served as the
President of Weis Associates, LLC, a consulting firm she founded focused on healthcare management, strategic planning and leadership development, since January 2014. She has also served as a Senior Advisor to Leavitt Partners, LLC, a health care
consulting firm, since February 2014 and as a Special Advisor to the President and Professor of Practice in the W. P. Carey School of Business and the College of Nursing and Health Innovation at Arizona State University, from August 2014 until June
2018. Previously, Ms. Weis was the Vice President and Chief Administrative Officer of Mayo Clinic, a nonprofit medical practice and medical research group, from 2007 until her retirement in December 2013. She joined Mayo Clinic in 1995 and held a
number of clinical and administrative leadership positions, including Chair of Administrative Services for the Mayo Clinic in Arizona, Chair of the Mayo Clinic Managed Care Department and Executive Director of Mayo Management Services, Inc. Ms. Weis
was also previously a member of the Mayo Clinic Board of Trustees and served as the Secretary for the Mayo Clinic Board of Governors. Prior to joining the Mayo Clinic, she was the Chief Operating Officer of Blue Care Network, a Health Maintenance
Organization, and the Emergency Department Manager for Lansing General Hospital. Ms. Weis </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has served on the Boards of Directors of RTI Surgical Holdings, Inc. (NASDAQ:RTIX), a leading global surgical implant company, since October 2014 and The Medical Memory, LLC, a Phoenix-based,
private company that facilitates recording of medical conversations with doctors and distributes them to patients and families, since July 2017. She previously served on the Boards of Directors of Sentry Insurance Company, a mutual insurance company
specializing in business insurance, from May 2015 until April 2019, and Traverse Global Healthcare, a Phoenix-based developer of U.S. - style healthcare facilities in global markets, from February 2014 until the company was dissolved in October
2016. Ms.&nbsp;Weis also served on the Michigan State University College of Nursing Board of Visitors and is a distinguished author and public speaker. She is Emeritus Assistant Professor in the Mayo Clinic College of Medicine and has also taught
healthcare leadership at the University of Minnesota&#146;s Carlson School of Management, Michigan State University, University of Wisconsin-LaCrosse, Lansing Community College and for the Michigan Hospital Association. Ms.&nbsp;Weis holds a BSN in
Nursing from Michigan State University and a Master&#146;s degree in management from Aquinas College. She also received an honorary Doctor of Science degree from Michigan State University. Ms.&nbsp;Weis has been named a Michigan State University
Distinguished Alumna and has received the Diana Award for Outstanding Business Women. She was also named one of the Top 25 Women in Healthcare by Modern Healthcare magazine for 2007 and 2013 and the National Association of Professional Women&#146;s
&#147;Woman of the Year Award&#148; for 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Important Additional Information and Where You Can Find It </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. (the &#147;Company&#148;), its directors and certain of its executive officers may be deemed to be participants in a solicitation of proxies from
the Company&#146;s shareholders at its 2020 Annual Meeting of Shareholders in connection with the director nominations disclosed above. Information regarding the Company&#146;s directors and executive officers and their respective interests in the
Company, by security holdings or otherwise, will be set forth in the Company&#146;s Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders, to be filed with the SEC, and reports filed by the Company and ownership forms filed by its
directors and executive officers with the SEC. The Company will furnish its Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders to shareholders entitled to vote at the meeting and will file a copy with the SEC. The Company urges
its shareholders to carefully read the Definitive Proxy Statement for its 2020 Annual Meeting of Shareholders, and any other relevant documents filed by the Company with the SEC, when available because they will contain important information.
Shareholders will be able to receive the proxy statement and other relevant documents free of charge at the SEC&#146;s website at www.sec.gov or at <U>www.mednax.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ABOUT MEDNAX </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MEDNAX, Inc. is a national health solutions
partner comprised of the nation&#146;s leading providers of physician services. Physicians and advanced practitioners practicing as part of MEDNAX are reshaping the delivery of care within their specialties and subspecialties, using evidence-based
tools, continuous quality initiatives, consulting services, clinical research and telemedicine to </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
enhance patient outcomes and provide high-quality, cost-effective care. The Company was founded in 1979, and today, through its affiliated professional corporations, MEDNAX provides services
through a network of more than 3,000 physicians in all 50 states and Puerto Rico. Additional information is available at <U>www.mednax.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Certain statements and information in this press release may be deemed to contain forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, Section&nbsp;27A of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include, but are not
limited to, statements relating to the Company&#146;s objectives, plans and strategies, and all statements, other than statements of historical facts, that address activities, events or developments that we intend, expect, project, believe or
anticipate will or may occur in the future. These statements are often characterized by terminology such as &#147;believe,&#148; &#147;hope,&#148; &#147;may,&#148; &#147;anticipate,&#148; &#147;should,&#148; &#147;intend,&#148; &#147;plan,&#148;
&#147;will,&#148; &#147;expect,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;positioned,&#148; &#147;strategy&#148; and similar expressions, and are based on assumptions and assessments made by the Company&#146;s management in light of
their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and
the Company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and
uncertainties. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the Company&#146;s most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and its Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> including the sections entitled &#147;Risk Factors&#148;, as well the Company&#146;s current reports on Form <FONT
STYLE="white-space:nowrap">8-K,</FONT> filed with the Securities and Exchange Commission, and include the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak on the Company and its financial condition and results of operations;
the effects of economic conditions on the Company&#146;s business; the effects of the Affordable Care Act and potential changes thereto or a repeal thereof; the Company&#146;s relationships with government-sponsored or funded healthcare programs,
including Medicare and Medicaid, and with managed care organizations and commercial health insurance payors; the Company&#146;s ability to comply with the terms of its debt financing arrangements; the impact of the divestiture of the Company&#146;s
anesthesiology medical group; whether the Company will be able to complete the divestiture of its radiology medical group and the terms of any such divestiture; the timing and contribution of future acquisitions; the effects of share repurchases;
and the effects of the Company&#146;s transformation initiatives, including its reorientation on, and growth strategy for, its pediatrics and obstetrics business. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>md-20200712.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-5 Build:20200707.2 -->
<!-- Creation date: 7/13/2020 5:04:58 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:md="http://www.mednax.com/20200712"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.mednax.com/20200712"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="md-20200712_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="md-20200712_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>md-20200712_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-5 Build:20200707.2 -->
<!-- Creation date: 7/13/2020 5:04:58 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>md-20200712_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-5 Build:20200707.2 -->
<!-- Creation date: 7/13/2020 5:04:59 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="md-20200712.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g82405g0713074008037.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g82405g0713074008037.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 2D# 2(  A$! Q$!_\0
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M?VMJ?_03O?\ P(?_ !H_M;4_^@G>_P#@0_\ C5.I((7N+B*",9DE<(H)ZDG
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MCF"M?PYXCOO"VJ?VCIXB^T>68P9$W  XSCWXK) ).!R3TK<'@WQ*1D:'>_\
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MKMCBU&*5CCEA6Y-W'>#?^1(T+_KP@_\ 0!6W4<$$5M;QP0QK'%&H1$48"@=
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MZLDQ@DD&UXD8F-QR&RO*_6J_A*>[FMKM999Y[..?;9SW";9)$QSG/7!R >]
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MNFTYKS2Y+:WU$A;>82!P6(R <<C(%6-#N)[CP@8[E'%U;Q26TH8')9 5S[Y
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:*** #-%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>d82405d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="md-20200712.xsd" xlink:type="simple"/>
    <context id="duration_2020-07-12_to_2020-07-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000893949</identifier>
        </entity>
        <period>
            <startDate>2020-07-12</startDate>
            <endDate>2020-07-12</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2020-07-12_to_2020-07-12">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-07-12_to_2020-07-12"
      id="Hidden_dei_EntityCentralIndexKey">0000893949</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-07-12_to_2020-07-12">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-07-12_to_2020-07-12">2020-07-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2020-07-12_to_2020-07-12">MEDNAX, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-07-12_to_2020-07-12">FL</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-07-12_to_2020-07-12">001-12111</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2020-07-12_to_2020-07-12">26-3667538</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-07-12_to_2020-07-12">1301 Concord Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-07-12_to_2020-07-12">Sunrise</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2020-07-12_to_2020-07-12">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-07-12_to_2020-07-12">33323</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2020-07-12_to_2020-07-12">(954)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2020-07-12_to_2020-07-12">384-0175</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2020-07-12_to_2020-07-12">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-07-12_to_2020-07-12">true</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-07-12_to_2020-07-12">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-07-12_to_2020-07-12">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2020-07-12_to_2020-07-12">Common Stock, par value $.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-07-12_to_2020-07-12">MD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2020-07-12_to_2020-07-12">NYSE</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-07-12_to_2020-07-12">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139806973135896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 12, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000893949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 12,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MEDNAX, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3667538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1301 Concord Terrace<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Sunrise<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-0175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $.01 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MK];[(^K^QJJL.!:NE(5#9G&YA6,]UZX!?+]6RK[?N)-F^4/!^!]02P,$%
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M"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ 4$GM4!PX9>H_ 0  / (   \
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M<F]P<R]A<' N>&UL4$L! A0#%     @ 4$GM4%XJW#SM    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 4$GM
M4)E<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " !02>U0;BEL2#($   T$   &
M@($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 4$GM
M4(.II0/4 0  ,@8   T              ( != P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " !02>U0EXJ[',     3 @  "P              @ %S#@
M7W)E;',O+G)E;'-02P$"% ,4    " !02>U0'#AEZC\!   \ @  #P
M        @ %<#P  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 4$GM4"0>
MFZ*M    ^ $  !H              ( !R!   'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 4$GM4&60>9(9 0  SP,  !,
M     ( !K1$  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&]Q(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d82405d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d82405d8k.htm">d82405d8k.htm</File>
    <File>d82405dex101.htm</File>
    <File>d82405dex102.htm</File>
    <File>d82405dex103.htm</File>
    <File>d82405dex104.htm</File>
    <File>d82405dex991.htm</File>
    <File>md-20200712.xsd</File>
    <File>md-20200712_lab.xml</File>
    <File>md-20200712_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d82405d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d82405d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "md-20200712_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "md-20200712_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "md-20200712.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "md",
   "nsuri": "http://www.mednax.com/20200712",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d82405d8k.htm",
      "contextRef": "duration_2020-07-12_to_2020-07-12",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d82405d8k.htm",
      "contextRef": "duration_2020-07-12_to_2020-07-12",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.mednax.com//20200712/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-20-191602-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-191602-xbrl.zip
M4$L#!!0    ( %!)[5 -.8EY4CH  -4K 0 -    9#@R-# U9#AK+FAT;>U]
M:U,;2;+V]S?B_0\5S.P&1$A"$F #]G ""VPS8S #S'CV?-DHJ4M2KUO=FKX
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MZL1E#H6TQ+M7=W8-2AW.71+8JD%/Q*GT*1_'3P$N#S%5!_@N$>LHX[A?7ZL
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MI>8H"W:4P.*8]O$57:@3K%O:"[.0(U_0 RXG/,WQ<B.FY583!U4@H:PZL7K
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MQ2%H$827\/:>.Q(<7"3^M$;6T4)_'ODQ<;4C$:"*PS+.\Y,@\MUGJ]6>F]>
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MAB[?,8T1IPW4T]I,OZ$=C=LRFJ0J+J6VX7'B>7DB.:"V,'&#95'[W3D)6A>
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M(ZS$J8\PLP!A-;/1+W;'*;'EZ8=+U#\AU:.)C24I1RPG9*\B:*%4'G2W#:/
MC_ GO"T%0YDB >M[RC=2XPBP!:W,"&6AVY.A&WVL;BKM%[DF:[\L,<)'C@I
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M-<Y[Q\5P8FM 3AMRHRT+;+SO/)I6=Y^7AB(M1C3;>_=#-/ZJC@E8]DN%!?H
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M&N@MGJT.(N0*8B'B08R;2>1(%K3'@+NMTJJH0QN\%O1.:?V#SG3R$#;H!9-
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M??WJ!*UPS@=[;L.@-_ME7NKQKF49"R=G^\%I Z_'&_6V()]=U58!X*%_$\-
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M(PS%KFW394>$]Z"J%?^I;]):L+R!Z$\_O#K:_0T^?'MV>/#R_P-02P,$%
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M#&A[%A?:#.8O3F^6YK6E031)*KA5_H/\H8IQ&=0EKJ>N@BR'-ZMADM$Y"^C
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M&9_-D7QP_="- G.E-?43E_'S8G&A<\@0! -M1)*555$/*E9$SXN$Y#X,%(.
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M 3K@F6CJJ#WL:K41]I'$:U/@H/1CK;MEJ^BO\-]X4Z(>^Q4^6%QP+F)'C[W
MAXF'K!U NS7/"G*N!192(*;/X&KABR"?@)RJZ@R%"W#&I,BG(+])CLN*2U5,
M02R7^/5,'Y0SE^\WD%8<W<%,M5#_KA.Y3Y!>L]^ TU<%"*JQG3/2@G1Y\?,X
MZQKB#>E95JB_K+0OT3PXC\B%"5POMR!Q?"HZ!I_T'AA>@U0%SWW3O>&6@Y,.
MNM,(68@T/O)W76,/FG3O(L1*<(J'7?L:V.F, BQSG PI6#,I7:]:U=#\VL^S
M*!CB!,Q;G<V(ZP'OQ?KJ;WAFM8Z)8T9H()TY8W<,)8M#20F[;=2<&(2"6*;
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M]ZU44;H"MY=Q1='SU@K'EY3.&X:4*HZ@3[R$IH/9TF#>DD/_LA%V4&*ON+S
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M',*;SD2#  #'=Q=[+RY(((1Q$'S,,_DQ7BX(PM0(:"8S("<818(,;)>E#9Y
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MPU_O!G!K,-:Y6(>PY2? 6_C:LH/0O>UBK,0_?MD_?'[<GJ@D@O\*_/KB^)&
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MP=E' $(%LTPGL?BD3(I_GQU\;-X"S>'1=P0G( H1//W.^=5E6[3>=R[;\-]
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MW=/(6Z)U;93"3XTR69*1>*.&9B:-H^63G):ID'958,'2;F^T23.1<RY"\TT
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M:N?Q#GW_T&JWW?<225Y?]=J='OUN8>!?]H".%ZT/_<Z)^U")K&7,KG EDII
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M+>A%M"ET5:LG>VII=%GUZ+WG+U6E;;)"\;Z2#1Q.P'&T@5(E9@R35(%YU0U
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MFEJD4=PC7.'#$5$SJOVADH-:ED0W%O>7&_B)KM+F@KCV#V5T)R94@B> -JP
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M-BP?$+IZR>^XU%OF-V"DNVCR>R#TGO\ 4$L#!!0    ( %!)[5#:A5($M00
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M+FAT;5!+ 0(4 Q0    ( %!)[5 8#RK ;$$  -54 0 0              "
M 7&6  !D.#(T,#5D97@Q,#(N:'1M4$L! A0#%     @ 4$GM4*">.$*#%@
M:FD  !               ( !"]@  &0X,C0P-61E>#$P,RYH=&U02P$"% ,4
M    " !02>U0XHC2,*(6  ##:0  $               @ &\[@  9#@R-# U
M9&5X,3 T+FAT;5!+ 0(4 Q0    ( %!)[5#/LT4G*2,  +AQ   0
M      "  8P% 0!D.#(T,#5D97@Y.3$N:'1M4$L! A0#%     @ 4$GM4,%/
MT(A? P  &@P   \              ( !XR@! &UD+3(P,C P-S$R+GAS9%!+
M 0(4 Q0    ( %!)[5 (W&*58@8  $A$   3              "  6\L 0!M
M9"TR,#(P,#<Q,E]L86(N>&UL4$L! A0#%     @ 4$GM4-J%4@2U!    "L
M !,              ( ! C,! &UD+3(P,C P-S$R7W!R92YX;6Q02P4&
/  D "0 P @  Z#<!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
